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ABSTRACT 
Acute coronary syndrome (ACS) results from thrombotic occlusion of an atherosclerotic 
coronary artery. Platelets are pivotal in arterial thrombosis and, as a result, preventative 
therapy has focussed on antiplatelet drugs. Currently, dual antiplatelet therapy with 
aspirin and a P2Y12 antagonist is the recommended treatment following ACS. New-
generation P2Y12 inhibitors (ticagrelor and prasugrel) offer potent and consistent 
antithrombotic effect. Despite this, recurrent events remain common. Mechanisms 
driving those events are not entirely clear.  
The protein arm of coagulation also plays an important role in arterial thrombosis, 
leading to fibrin formation and stabilisation of thrombus. Although the cellular arm of 
coagulation may be optimally inhibited with contemporary therapy, the protein arm 
remains largely unaffected. Adverse fibrin clot dynamics have been associated with 
vascular conditions and with conditions closely related to worse outcome such as 
diabetes mellitus (DM). It is, therefore, plausible that adverse fibrin-rich clots that resist 
lysis are responsible for some of the recurrent events.  
In my PhD, I have studied fibrin clot properties in 4,354 plasma samples, collected at 
hospital discharge, and 4,032 plasma samples, collected at 1-month, from ACS patients 
in the PLATelet inhibition and patient Outcome (PLATO) trial. I found that adverse 
fibrin clots that resisted lysis at hospital discharge independently predicted the combined 
outcome of cardiovascular (CV) death and spontaneous myocardial infarction with no 
association with PLATO-defined major bleeding events. 
Following resolution of inflammation at 1-month, fibrin clot density (determined by 
maximum turbidity) was attenuated but fibrin clot lysis potential remained relatively 
stable, showing consistent relationships with high-risk conditions such as DM, peripheral 
artery disease and chronic kidney disease.  
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Moreover, increased fibrin density and lysis inefficiency strongly correlated with 
inflammatory and prognostic biomarkers (leukocyte count, high-sensitivity C-reactive 
protein, high-sensitivity troponin T, cystatin C, N-terminal pro B-type natriuretic peptide 
and growth differentiation factor-15) giving us mechanistic insights into worse 
outcomes. With the cellular arm effectively targeted by contemporary dual antiplatelet 
therapy, fibrin lysis inefficiency constitutes a therapeutic target to mitigate the residual 
risk post ACS.  
I have also studied the ability of different anticoagulants to modulate fibrin clot 
properties as a novel approach to establish treatment effects. Fibrin clot lag time appeared 
sensitive to very low concentrations of rivaroxaban, apixaban and fondaparinux and high 
concentrations promoted fibrinolysis. Therefore, fibrin clot lag time seems promising as 
a novel assay to monitor treatment but ex-vivo studies are needed to confirm these 
findings.  
In an attempt to optimise antithrombotic therapy in ACS patients, I have investigated 
enoxaparin infusion in ST-elevation myocardial infarction (STEMI) patients undergoing 
primary angioplasty as a novel approach to mitigate acute thrombotic risk. Absorption 
of oral P2Y12 inhibitors is delayed in opiate-treated STEMI patients and this may 
constitute a risk for acute stent thrombosis. In 20 patients undergoing primary 
angioplasty, a novel regimen consisting of a bolus of enoxaparin 0.75 mg/kg followed 
by an infusion of 0.75 mg/kg/6 hours offered sustained anti-Xa levels and improved 
fibrin clot lysis potential throughout the infusion. No patient suffered a thrombotic 
complication despite a high prevalence of poor P2Y12 inhibition in opiate-treated 
patients. This study offers preliminary pilot data to support the hypothesis that this 
regimen would be sufficient to circumvent the delayed onset of action of oral P2Y12 
inhibitors.  
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1 Acute coronary syndromes: pathophysiology and optimising 
antithrombotic therapy 
Publications resulting from this chapter:  
1) Sumaya W, Storey RF. The challenges of antithrombotic therapy in patients with 
left ventricular thrombosis. Eur Heart J. 2018;39:209-211. 
 
2) Sumaya W, Storey RF. Dual antiplatelet therapy following acute coronary 
syndromes: optimal regimens and duration of therapy. Br J Cardiol. 
2017;24(suppl 1):S10-S15.  
3) Sumaya W, Storey RF. Ticagrelor: Effects Beyond the P2Y12 Receptor. Interv 
Cardiol Clin. 2017;6(1):49-55. 
Including some of the published material in this chapter does not violate copyright 
agreements and is in agreement with the co-author.  
1.1 Abstract 
In the 1980s, we learnt that thrombosis in atherosclerotic coronary arteries is the usual 
cause of acute coronary syndrome (ACS). Since then, our understanding of the disease 
process has evolved, leading to the development of effective antithrombotic treatments. 
This has revolutionised therapy, facilitating revascularisation with percutaneous 
coronary intervention (PCI) and greatly improving clinical outcomes. However, despite 
this revolution, approximately 20% die or suffer recurrent events in the first year 
following ACS. The downside to antithrombotic treatment is the increased risk of 
bleeding and striking the right balance between ischaemia and bleeding is challenging. 
Detailed understanding of the pathophysiology is key to tackling this issue. Markers of 
the disease process could enhance our understanding and may guide treatment. In this 
chapter, I will consider the pathophysiology of ACS, currently available antithrombotic 
treatments and how markers of increased thrombotic risk could guide treatment in the 
future. 
1.2 Background 
Cardiovascular disease remains amongst the biggest killers in the world with over 30% 
of global deaths secondary to cardiovascular disease and approximately 7.4 million 
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deaths attributable to coronary artery disease (CAD) (1). Acute presentation of CAD in 
the form of ACS is usually caused by thrombus formation in an atherosclerotic coronary 
artery, secondary to a complex process that involves activation of both the cellular and 
protein arms of coagulation. Antithrombotic treatment has a key role in the management 
of ACS and consists of anticoagulants and antiplatelet therapy in the acute setting with 
preventative antiplatelet therapy continued in the long term (2, 3).  
Despite contemporary medical treatment, ACS continues to carry significant mortality 
and morbidity, with a large proportion of patients experiencing recurrent events (4). In 
recent randomised controlled trials (RCTs) using potent antiplatelet regimens, 
approximately 10% of patients died or had a cardiovascular event within one year of 
ACS (5, 6) with even a higher rate of adverse clinical outcomes in real-life settings and 
outside RCT conditions (7, 8). 
One option to improve outcomes is the introduction of other potent antithrombotic 
treatments and low-dose of rivaroxaban, a direct factor Xa inhibitor, has shown 
promising results but the increased risk of bleeding has caused concern and limited 
widespread use (9).   
One caveat to antithrombotic therapy is the desire to have “one therapy for all”, when 
such therapy may have differing effects in various individuals. The challenge is to choose 
the right patient cohort in whom escalated treatment is necessary. Understanding the 
disease process is essential to help us identify those individuals. Certain disease markers 
could also help risk stratify patients. In this section, I will review the pathophysiology of 
ACS, currently available treatment options and some of the thrombotic and inflammatory 
markers of worse outcome.  
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1.3 Pathophysiology 
 
1.3.1 Atherosclerosis 
Atherosclerosis is a complex pathological process where endothelial dysfunction, 
inflammation and thrombosis play inter-related roles (10).   
Though a single layer of cells forming the inner lining of blood vessels, the endothelium 
plays many important roles including making a barrier, maintaining vascular tone, and 
regulating thrombosis and inflammation. Endothelial cells produce nitric oxide (NO) and 
prostacyclin (prostaglandin-I2: PG-I2). Both inhibit platelets and lead to vasodilation. 
(11-14). Traditional CAD risk factors, including hypertension, smoking, hyperlipidaemia 
and diabetes, have all been associated with endothelial dysfunction (15-19).  
Cytokines like tumour necrosis factor-α (TNFα) and interferon-g (IFNg) can also 
influence endothelial function. They change the distribution of endothelial cadherin-
catenin complexes and increase intra-cellular calcium levels, thereby activating myosin 
light chain kinase (20, 21). This facilitates leukocyte migration to the intima. Circulating 
leukocytes (mainly monocytes and some lymphocytes) bind to vascular cell adhesion 
molecules expressed on activated endothelial cells and then migrate to the intima (22). 
Chemokines such as monocyte chemoattractant protein–1 (MCP-1) enhance leukocyte 
migration by activating G-coupled protein receptors (23). Circulating cholesterol in the 
form of low-density lipoprotein migrates to the intima where it is oxidized (24). In the 
intima, complex inflammatory events take place mediated by different cytokines (Figure 
1-1). Macrophage colony-stimulating factor (M-CSF) helps monocytes mature into 
macrophages (25). Macrophages engulf oxidized LDL through scavenger receptors to 
form foam cells. Platelet-derived growth factor (PDGF) and other chemokines stimulate 
smooth muscle cell (SMC) migration from the tunica media to the intima. SMCs express 
tissue factor (TF). Interleukin (IL)1, TNFα and IFNg further amplify inflammatory 
 12 
responses and promote apoptosis of foam cells and SMCs. They also have an impact on 
endothelial cells, inducing production of pro-coagulant factors and inhibiting release of 
antithrombotic factors (26). As plaques progress further, debris from apoptotic SMCs 
and foam cells form the necrotic core of the plaques. Macrophages also produce TF and 
metalloproteinases (MMPs). MMPs degrade collagen, leading to thinning of the fibrous 
cap. (Figure 1-1) 
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Figure 1-1: Schematic drawing illustrating the pathophysiology of atherosclerosis  
Under normal circumstances, the endothelium (top) forms a barrier and secretes nitric 
oxide (NO) and prostaglandin-I2 (PG-I2) and these inhibit platelets.  Cytokines 
interferon-g (IFNg) and tumour necrosis factor-α (TNFα) contribute to the activation of 
endothelial cells (ECs). Activated ECs express vascular cell adhesion molecules 
(VCAMs) and these bind to circulating leukocytes. Leukocytes then migrate to the 
intima. Monocyte chemoattractant protein-1 (MCP-1) enhances leukocyte migration. 
LDL migrates to intima where it is oxidised. Monocytes mature into macrophages 
through the action of macrophage colony stimulating factor (M-CSF).  Macrophages 
express scavenger receptors, taking in oxidised LDL to form foam cells. They also 
express the pro-coagulant molecule tissue factor (TF). Monocytes and macrophages 
produce multiple cytokines, in particular interleukin-1 (IL1) and TNFα, and these have 
direct effect on endothelial function, induce apoptosis and promote T helper 1 cell 
responses (TH1). The few TH1 cells produce IFNg and TNFα, both of which influence 
ECs and amplify the inflammatory response. Smooth muscle cells (SMCs) migrate from 
the intermediate layer to the intima in response to chemokines such as platelet-derived 
growth factor (PDGF). They too express TF and produce collagen which forms the 
fibrous cap. Macrophages produce metalloproteinases (MMPs). MMPs remodel collagen 
structure leading to thin fibrous caps. Debris from apoptotic cells (SMCs and foam cells) 
accumulates to form the necrotic core in atherosclerotic plaques. 
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1.3.2 Arterial thrombosis  
Platelets assume the driving seat when it comes to arterial thrombosis. Subsequent to 
plaque rupture, they adhere to exposed sub-endothelial agonists, such as collagen and 
von Willebrand factor (vWF) through platelet glycoprotein (GP) VI and Ib receptors, 
respectively, in order to produce an initial platelet plug. Integrin a2b1 also plays a role 
mediating platelet adhesion to collagen (27).  The sub-endothelial ligands activate 
platelets, which change in shape, express multiple receptors and secrete soluble agonists 
including thromboxane A2 (TXA2) and adenosine diphosphate (ADP). TXA2 activates 
platelets further and ADP amplifies and sustains platelet activation predominantly 
through platelet P2Y12 receptors, leading to further expansion of the platelet-rich 
thrombus (Figure 1-2) (28). In parallel to platelet activation, exposed TF binds to 
activated factor VII and this activates factors IX and X. Activated factor X cleaves 
prothrombin to form thrombin (Figure 1-2). Thrombin has multiple actions including: 1) 
further activation of platelets through its action on platelet protease-activated receptors 
(PAR1/PAR4); 2) activation of the coagulation system resulting in the conversion of 
soluble fibrinogen into insoluble fibrin network (28-32). Thrombin can also be produced 
on the surface of activated platelets through phospholipid scramblase activity (33). 
However, pre-clinical data suggest that thrombin may play a greater role in stabilisation 
of the core of arterial thrombus rather than its expansion (34).  
Additionally, activated platelets lead to further recruitment of inflammatory cells through 
release of chemokines and other cytokines from their α-granules (28, 35, 36). Activated 
platelets cross-link by binding with formed fibrin through platelet integrin receptor αIIbβ3, 
otherwise known as GPIIb/IIIa.  
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Figure 1-2: Schematic drawing of arterial thrombosis  
Following plaque rupture, platelets adhere to von Willebrand factor (vWF) and collagen. 
Activated platelets undergo shape change, express multiple receptors, release adenosine 
diphosphate (ADP) from dense granules and produce thromboxane A2 (TXA2). ADP 
amplifies platelet activation and together with TXA2 lead to further expansion of the 
platelet plug. Thrombin is also produced but primarily stabilises the core thrombus. 
Multiple inflammatory mediators and clotting factors are also released from platelet α-
granules. Serpins that limit fibrinolysis including plasminogen activation inhibitor-1 
(PAI-1) (37), a2 plasmin inhibitor (a2 PI) (38) and protease nexine 1 (39) (not shown) 
are also secreted. Platelet derived PAI-1 accounts for a great proportion of plasma PAI-
1 (37); ‘a’ denotes activated clotting factor.  
 
1.3.3 Regulatory mechanisms 
Despite the systemic nature of atherosclerosis risk factors, atherosclerotic plaques in the 
coronary arterial tree tend to be localized, at least at early stages of the disease. This is 
likely to be secondary to local variation in haemodynamic factors and shear stress levels; 
in areas of steady laminar flow, vasoprotective genes are up-regulated in contrast to areas 
exposed to turbulent flow (40). Anti-inflammatory cytokines include IL10, IL33, IL35, 
IL1 receptor antagonist (IL1ra) and transforming growth factor β (TGFβ) (26).  
Intrinsic mechanisms to control thrombosis include protein C, thrombomodulin, 
heparin/antithrombin, tissue factor pathway inhibitor (TFPI) and tissue plasminogen 
activator (tPA) (Figure 1-3). Protein C inhibits activated factors V and VIII. TFPI inhibits 
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TF and factor VII dependent pathway. Heparin inhibits thrombin and other activated 
factors (IX, X, XI). Thrombomodulin redirects thrombin activity to activate protein C 
and thrombin-activatable fibrinolysis inhibitor (TAFI). Plasminogen is cleaved by tPA 
to produce plasmin and this degrades fibrin, initiating fibrinolysis (32). Plasmin acts on 
the carboxy termini in fibrin, cleaving the αC domain and subsequently cleaving more 
fragments moving towards the E domain  (Figure 1-4) (41). This produces fibrin 
degradation products (42) and D-dimer is the most commonly used as a biomarker. D-
dimer also interacts with monocytes promoting IL6 production inducing hepatocytes’ 
production of both fibrinogen and C-reactive protein (CRP) (43).  
Plasminogen activation inhibitor-1 (PAI-1) is the main enzyme limiting tPA’s activity. 
a2-antiplasmin forms a complex with plasmin and limits lysis activity. TAFI breaks the 
positive feedback loop between fibrin and plasmin by cleaving off lysine residues in the 
C terminal of fibrin (44).  
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Figure 1-3: Fibrin clot formation, lysis and antifibrinolytic pathways 
Tissue factor pathway inhibitor (TFPI) inhibits the pathway activated by factor VII and 
von Willebrand factor (vWF). Tissue plasminogen activator (tPA) initiates internal 
fibrinolysis by cleaving plasminogen to produce plasmin. Thrombomodulin redirects 
thrombin activity to activate protein C (not shown) and thrombin-activatable fibrinolysis 
inhibitor (TAFI). TAFI inhibits plasmin and its production.  α2 plasmin inhibitor (α2-PI) 
inhibits plasmin and plasminogen activator inhibitor-1 (PAI-1) inhibits plasminogen 
conversion by inhibiting the action of tPA. 
 
1.4 Diagnosis  
The diagnosis of ACS has three elements: clinical assessment, electrocardiograph (ECG) 
assessment and measurement of markers of myocardial necrosis (primarily troponin). 
Patients usually present with ischaemic chest pain at rest or minimal exertion. Once ACS 
is suspected, the ECG is indispensable. ST-elevation myocardial infarction (STEMI) is 
usually diagnosed by persistent ST-segment elevation (≥ 1 mV) in two contiguous leads. 
In the absence of persistent ST-segment elevation, certain ECG changes (transient ST-
segment elevation, ST-segment depression, T wave inversion) could indicate a diagnosis 
of non-ST-elevation ACS (NSTE-ACS). NSTE-ACS can be classified into unstable 
angina or non-ST-elevation myocardial infarction (NSTEMI) on the basis of troponin 
measurements (45).  
1.5 Preventative antithrombotic treatment  
It was the 1980s when the paradigm shift in our understanding of ACS took place. The 
hypothesis of coronary artery spasm leading to ACS was predominant when Dr. Michael 
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Davies confirmed, for the first time, the presence of thrombotic lesions in the coronary 
arteries of those who died of ACS (46). This was the milestone that prompted a body of 
research to focus on antithrombotic treatment. In this section, I will review currently 
available treatment. 
1.5.1 Antiplatelet therapy 
Aspirin 
Aspirin (acetylsalicylic acid) irreversibly acetylates platelet cyclooxygenase (COX) -1, 
blocking its activity. COX-1 converts arachidonic acid to PGH2/G2 and these form 
substrates for thromboxane synthase, leading to the production of TXA2. TXA2 is a 
potent vasoconstrictor and also activates platelets through thromboxane prostanoid 
receptors (47). Aspirin indirectly exerts paradoxical effects on platelets at higher doses; 
as well as inhibiting platelet COX-1 enzyme, it also acetylates endothelial cell COX-2, 
thereby inhibiting PG-I2 production (48) and  reducing platelet inhibition through the 
PG-I2 pathway.  
Evidence of efficacy of aspirin emerged in 1983 when a significant 51% risk reduction 
of recurrent ACS or death was demonstrated in unstable angina patients receiving aspirin 
as compared to placebo (49). These results were further echoed in several other studies 
(50, 51) and, in patients with STE-ACS, aspirin reduced vascular death significantly by 
23% (52). 
A wide range of doses of aspirin has been used but the Antithrombotic Trialists’ 
Collaboration completed a meta-analysis of randomised trials and concluded that low 
maintenance doses of 75 to 150 mg are as effective as higher doses but higher doses were 
needed for loading in the hyper-acute setting (53).  
The OASIS–7 trial compared lower maintenance dose aspirin (75 – 100 mg) to higher 
doses (300 – 325 mg) and found no difference in clinical efficacy or safety (at 30 days) 
when combined with clopidogrel in ACS patients referred for invasive treatment (54). 
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Gastrointestinal bleeding was found to be marginally higher in the higher-dose aspirin 
group (0.4% vs. 0.2%, p = 0.04).  
Although aspirin’s pharmacodynamic effects are evident with “extra low” doses (20-40 
mg daily) (55, 56), clinical efficacy at those levels has not been assessed.  
P2Y12 receptor antagonists 
Ticlopidine is a 1st generation thienopyridine. Its active metabolite (thiolactone) 
irreversibly blocks platelet P2Y12 receptors (57). Ticlopidine showed promising results 
in reducing ischaemic events following PCI, especially in ACS patients, and dual 
antiplatelet therapy (DAPT) was first tested with ticlopidine (58-61). Its success, 
however, was hampered by a profile of side effects including thrombotic 
thrombocytopenic purpura, which carries a high mortality (62).  
Clopidogrel is a prodrug that also belongs to the thienopyridine family. Its active 
metabolite irreversibly inhibits platelet P2Y12 receptors. Clopidogrel metabolism is 
complex, requiring conversion to the active metabolite by the cytochrome P450 (CYP) 
enzymes in the liver, and the majority (85%) of clopidogrel is catabolised to inactive 
metabolites by plasma carboxylesterases (63). This is largely responsible for the wide 
inter-individual variability in platelet reactivity during treatment with clopidogrel and 
“poor response” to clopidogrel has been shown to increase ischaemic risk (64).  
In NSTE-ACS patients, clopidogrel in addition to aspirin was tested in the CURE study. 
Clopidogrel, for 3 to 12 months post NSTE-ACS, reduced major adverse cardiovascular 
events (MACE) compared to placebo (9.3% vs. 11.4%, p < 0.001). Despite a trend 
towards better cardiovascular mortality with clopidogrel, MACE reduction was primarily 
driven by a reduction in non-fatal myocardial infarction (MI). There was no significant 
difference in terms of life-threatening or intracranial bleeds but clopidogrel resulted in a 
significant increase in major bleeding events (3.7% vs 2.7%, p = 0.001) (65). Patients 
received clopidogrel at randomisation (within 24 hours of presentation, pre-PCI) and 
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those requiring PCI in the placebo arm received open-label clopidogrel or ticlopidine for 
~ 4 weeks post PCI. Patients pre-treated with clopidogrel had a 31% reduction in the risk 
of MI or cardiovascular death (p = 0.002) (66).  
Clopidogrel is the only P2Y12 inhibitor tested in conjunction with aspirin and 
thrombolysis in STEMI patients. The addition of clopidogrel offered a significant 36% 
risk reduction in occlusion of the infarct-related artery, recurrent MI or death (67). In 
medically-treated STE-ACS patients, clopidogrel in addition to aspirin reduced MACE 
by 9% (p = 0.002) (68).  
Prasugrel is another thienopyridine prodrug. Its active metabolite is chemically similar 
to that of clopidogrel and also inhibits the P2Y12 receptor irreversibly. It provides more 
rapid and potent platelet inhibition as compared to clopidogrel due to more efficient 
active metabolite formation, starting with intestinal esterase followed by a one-step 
conversion in the liver by multiple CYP enzymes (69). Prasugrel, compared to 
clopidogrel, reduced MACE (9.9% vs. 12.1%, p < 0.001) in PCI-treated ACS patients in 
the TRITON-TIMI 38 trial (6), an outcome that was predominantly driven by a reduction 
in MI (7.4% vs. 9.7%, p < 0.001). Patients with NSTE-ACS were randomised only if PCI 
was indicated following coronary angiography. STE-ACS patients were included either 
following initial medical management and subsequent coronary angiography or if they 
were planned to receive primary PCI. Patients with diabetes and STE-ACS had the 
biggest reduction in ischaemic events. The downside was an increase in TIMI-defined 
major bleeding, including life-threatening bleeds, in the prasugrel-treated group (2.4% 
vs. 1.8%, p = 0.03). There was also a marginal but significant increase in fatal bleeding 
with prasugrel (0.4% vs. 0.1%, p = 0.002). Despite this, subgroup analyses suggested net 
clinical benefit except for those with history of stroke, low body weight (<60 kg) or age 
> 75 years (6).  
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The superior efficacy of prasugrel compared to clopidogrel was not replicated in 
medically-treated ACS patients in the TRILOGY trial (70). Interestingly, major bleeding 
was similar in both clopidogrel- and prasugrel-treated patients. This difference in 
bleeding profile compared to the previous trial might be explained by a reduction in 
prasugrel dose in patients with low body weight (< 60 kg) and those > 75 years old (70).  
The ACCOAST trial compared prasugrel pre-treatment in NSTE-ACS patients to 
treatment post coronary angiography only for those undergoing PCI and found no 
difference in ischaemic endpoints but significantly higher rates of major bleeding (2.6% 
vs. 1.4%, p = 0.006) (71). Although this trial had limitations (over 50% of procedures 
were performed through the femoral approach, the study protocol did not recommend a 
wash-out period prior to coronary artery bypass surgery (CABG) and the majority of 
bleeding events were related to access site and surgery), this has put an end to prasugrel 
treatment in NSTE-ACS patients prior to coronary angiography (2).  
Ticagrelor belongs to a different class (cyclopentyl-triazolopyrimidines). It acts directly 
and reversibly blocks platelet P2Y12 receptors in a non-competitive pattern (allosteric 
inhibition). Being an active drug, ticagrelor achieves rapid platelet inhibition and 
minimises any chance of inter-individual variance in pharmacodynamic response (72). 
Ticagrelor is metabolised via hepatic CYP3A and consequently concomitant use of 
strong CYP3A inducers or inhibitors is contraindicated (73). Ticagrelor also has a more 
rapid and consistent offset of action compared to clopidogrel – a desired effect should 
serious bleeding occur or if major surgery is planned (72).  
Ticagrelor (90 mg twice daily) reduced MACE in moderate- to high-risk ACS patients 
compared to clopidogrel in the PLATO trial (5) (9.8% vs. 11.7%, p < 0.001). This was 
driven by a reduction in MI (5.8% vs. 6.9%, p = 0.005) and cardiovascular death (4% vs. 
5.1%, p = 0.001). Death from any cause was also reduced in ticagrelor-treated patients 
(4.5% vs. 5.9%, p < 0.001). Although overall major, fatal and life-threatening bleeding 
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rates were similar in both groups, non-CABG major bleeding was more with ticagrelor 
(4.5% vs. 3.8%, p = 0.03). Intracranial haemorrhage was also marginally increased with 
ticagrelor (0.3% vs. 0.2%, p = 0.06). Other important adverse effects of ticagrelor 
included dyspnoea (13.7% vs. 8.7%, p < 0.001) and more frequent ventricular pauses in 
the first week of treatment (5.8% vs. 3.6%, p = 0.01). Despite this, there was no increase 
in syncope or pacemaker implantation and the majority of dyspnoea events were mild or 
moderate with a minority having to discontinue treatment (74). More reassuringly, 
ticagrelor treatment did not have negative effects on cardiac or pulmonary function (75, 
76). Subgroup analyses confirmed consistent benefit with ticagrelor, including patients 
with STE-ACS (77), diabetes mellitus (DM) (78) or chronic kidney disease (CKD) (79) 
and the elderly (80). The benefit of ticagrelor was attenuated in patients recruited in the 
United States (US). Although this might have been due to chance (the US cohort was 
only ~ 8% of the PLATO patients), the majority of patients in the US were receiving a 
higher maintenance dose of aspirin (> 300 mg daily) (81). This raised the hypothesis of 
a negative interaction between higher doses of aspirin and ticagrelor, which remains to 
be further explored.  
Ticagrelor also blocks cellular uptake of adenosine by erythrocytes and other cells 
through inhibition of the equilibrative nucleoside transporter 1 (ENT-1) (82, 83). It 
remains uncertain whether this explains some of ticagrelor’s beneficial effects as well as 
some of its side effects (84). 
One caveat to oral P2Y12 inhibitors is the delayed onset of action in patients presenting 
with STE-ACS. In STE-ACS patients, especially those pre-treated with opiates, slow 
gastric transit might delay absorption and as a result pharmacodynamic effects can be 
delayed by up to 6-8 hours (85-87). This can increase the risk of stent thrombosis (88, 
89). Approaches to deal with this issue include GP IIb/IIIa inhibitors (GPIs) or cangrelor 
(an intravenous P2Y12 inhibitor). However, GPIs increase the risk of major bleeding (90) 
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and a 2-hour infusion of cangrelor might not be sufficient in all patients. Furthermore, 
costs associated with either of these approaches might limit wide-spread use. Studies to 
assess alternative approaches to deal with this issue are needed.  
Landmark clinical trials discussed above are summarised in table 1-1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1-1: Summary of landmark dual antiplatelet therapy trials 
Study and population Intervention Outcomes 
CURE: 12,562 NSTE-
ACS patients within 24 
hrs of presentation 
Clopidogrel 300 mg (at 
presentation) followed by 75 
mg OD for 3-12 months vs. 
placebo 
MACE: 9.3% vs. 11.4%; P < 0.001  
CV death: 5.1% vs. 5.5%; MI: 5.2% vs. 6.7% 
Major bleed: 3.7% vs. 2.7%; P = 0.001 
TRITON-TIMI 38: 
13,608 PCI-treated 
ACS patients 
Prasugrel 60 mg followed by 
10 mg OD vs. clopidogrel 300 
MACE: 9.9% vs. 12.1%; P < 0.001 
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(Following 
angiography in NSTE-
ACS and planned PPCI 
in STE-ACS)   
mg followed by 75 mg OD for 
6-12 months  
CV death: 2.1% vs. 2.4%; MI 7.3% vs. 9.5% 
Major bleed: 2.4% vs. 1.8%; P = 0.03 
Fatal bleed: 0.4% vs. 0.1%; P = 0.002 
TRILOGY-ACS: 
9,326 NSTE-ACS 
patients treated 
conservatively 
Prasugrel 60 mg followed by 
10 mg OD* vs. clopidogrel 300 
mg followed by 75 mg OD up 
to 30 months.  
*In patients < 60 kg or ³ 75 yrs 
– Prasugrel dose adjusted to 
30 mg followed by 5 mg OD.   
MACE: 13.3% vs. 13.9%; P = 0.45 
Major bleed: 1.9% vs. 1.5%; P = 0.1 
PLATO: 18,624 ACS 
patients within 24 hrs 
of presentation 
Ticagrelor 180 mg followed by 
90 mg BD vs. clopidogrel 300-
600 mg followed by 75 mg OD 
up to 12 months.  
MACE: 9.8% vs. 11.7%; P < 0.001 
CV death: 4% vs. 5.1%; MI 5.8% vs. 6.9% 
Major bleed: 4.5% vs. 3.8%; P = 0.03 
Fatal bleed: 0.3% vs. 0.3%; P = 0.66 
MACE: major adverse cardiovascular events; NSTE-ACS: non-ST-elevation acute 
coronary syndrome; STE-ACS: ST-elevation acute coronary syndrome; CV: 
cardiovascular; OD: once daily; BD: twice daily. 
 
Dual antiplatelet therapy beyond the 12 months 
The PEGASUS-TIMI 54 trial (91) assessed the efficacy and safety of ticagrelor 60 mg 
or 90 mg twice daily in patients with MI 1 to 3 years previously. 21,162 patients were 
randomised to placebo, ticagrelor 60 mg or ticagrelor 90 mg. All patients received aspirin 
(75-150 mg daily). Patients were at least 50 years of age with one additional marker of 
increased risk (age ³ 65 years, DM requiring treatment, an additional previous MI, 
multivessel CAD or CKD not requiring dialysis). Patients with stroke (ischaemic or 
haemorrhagic), central nervous system tumour, or intracranial vascular abnormality, or 
those treated with anticoagulants, cilostazol or dipyridamole were excluded. The trial 
also excluded patients with gastrointestinal bleed within 6 months and those who had 
undergone major surgery within 4 weeks. Both the 60-mg and 90-mg twice-daily doses 
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of ticagrelor reduced 3-year MACE rates compared to placebo (7.77% vs. 9.04%, p = 
0.004 and 7.85% vs. 9.04%, p = 0.008, respectively). Pooled analysis of both ticagrelor 
groups showed a non-significant trend towards improved cardiovascular mortality with 
ticagrelor compared to placebo (2.9% vs. 3.39, p = 0.06). There was no increase in rates 
of fatal or intracranial bleeding with ticagrelor. There was, however, a significant 
increase in TIMI-major bleeding with both doses (60 mg and 90 mg) compared to 
placebo (2.3% vs. 2.6% vs. 1.1%, respectively). Dyspnoea was significantly more 
frequent in ticagrelor-treated patients and this led to higher discontinuation rates. 
Ticagrelor 60 mg was associated with numerically lower rates of dyspnoea compared to 
90 mg but nevertheless resulted in discontinuation of therapy in 4.55% of cases. 
However, it should be borne in mind that very few patients in PEGASUS-TIMI 54 had 
been exposed to ticagrelor previously so it is highly likely that lower rates of 
discontinuation would be seen in patients continuing ticagrelor after tolerating this for 1 
year post-ACS. Gout was also marginally increased in ticagrelor-treated patients 
attributable to the effect of ticagrelor on serum uric acid levels (91).  
From the trial results overall, it is estimated that 42 major cardiovascular events per year 
would be prevented for every 10,000 patients treated with ticagrelor 60 mg at the cost of 
31 additional non-fatal TIMI major bleeds per year (91). A more favourable net benefit 
might be seen when ticagrelor therapy is extended without interruption after initial 1 year 
of treatment. 
Pharmacodynamic assessment showed ticagrelor 60 mg to provide potent and consistent 
platelet inhibition that is comparable to ticagrelor 90 mg in all compliant patients, 
explaining why the efficacy of the 60-mg and 90-mg doses was almost identical in 
PEGASUS-TIMI 54 (92).  
DM and peripheral artery disease (PAD) patients accrued greater absolute risk reduction 
of MACE with ticagrelor (1.5% and 4.1% respectively), including a 22% relative 
 26 
reduction in cardiovascular mortality in patients with DM (93, 94). Absolute excess risk 
of TIMI-major bleeding was also attenuated in patients with PAD (0.12%) (94). Patients 
with CKD (GFR < 60 ml/min) also had a robust absolute risk reduction of MACE (2.7%) 
with similar bleeding risk to those without kidney dysfunction (95).  
The DAPT study (96) assessed the safety and efficacy of 30-months’ treatment with 
DAPT (aspirin + clopidogrel/prasugrel) following PCI with drug-eluting stents (DES). 
9961 patients, who had received 12 months of DAPT post PCI with DES, were 
randomised to either continued DAPT with clopidogrel (65%) or prasugrel (35%) for a 
further 18 months or monotherapy with aspirin. Only 26% of patients had PCI for ACS 
and the trial excluded patients with MACE or significant bleeding in the 12 months’ 
period post PCI. Prolonged DAPT resulted in a reduction in rates of definite stent 
thrombosis (0.3% vs. 1.2%) and MACE (4.3% vs. 5.9%, p < 0.001) (96). This was 
primarily driven by a reduction in MI, both related and unrelated to stent thrombosis. 
There was no effect on cardiovascular mortality but all-cause mortality was numerically 
higher in the continued therapy group (2% vs. 1.5%, p = 0.05), mainly due to excess non-
cardiovascular mortality with prolonged therapy.  
Prolonged thienopyridine-based DAPT had previously been assessed in multiple smaller 
trials with no clear benefit of prolonged therapy (97-99). However, a collaborative meta-
analysis that included the subgroups with an index event of MI and the 21,162 patients 
from the PEGASUS-TIMI 54 study showed that prolonged therapy reduced MACE 
(6.4% vs. 7.5%, p = 0.001) and reduced cardiovascular death (2.3% vs. 2.6%, p = 0.03) 
with no significant increase in non-cardiovascular death (100).  
Shorter duration dual antiplatelet therapy 
In cases of heightened bleeding risk or when interruption to DAPT is anticipated, it might 
become necessary to stop DAPT. Trials assessing short durations of DAPT (3-6 months) 
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post PCI with modern second-generation DES have shown comparable safety with 12-
months’ therapy (101, 102). Furthermore, polymer-free DES were superior to bare-metal 
stents with 1-month DAPT post PCI (103). These trials, however, have primarily 
recruited low-risk stable patients and were designed to confirm the safety of these devices 
in terms of late stent thrombosis. They have also used clopidogrel-based DAPT and 
therefore the results cannot be generalised to ticagrelor-based DAPT in patients with 
ACS.   
Switching from a potent P2Y12 inhibitor to clopidogrel after one month of therapy in 
ACS patients undergoing PCI resulted in reduced major bleeding risk in the TOPIC trial 
(104). However, the trial only recruited patients who were stable during the first month 
after PCI and was not powered to detect a difference in ischaemic outcomes. A similar, 
but guided approach was trialled in the Tropical-ACS trial (105). One week of prasugrel-
based DAPT following PCI in ACS patients, followed by de-escalation of treatment to 
clopidogrel (to switch back to prasugrel in non-responders based on platelet function 
testing), was non-inferior to standard treatment with prasugrel. Major bleeding events 
did not significantly differ in the two treatment approaches raising the question of benefit 
of such approach. Taking these two trials into consideration, de-escalation of therapy 
may be a useful approach in patients with high bleeding risk following ACS.  
1.5.2 Anticoagulants 
The notion of using anticoagulants following ACS to offer long-term secondary 
prevention is far from new. Anticoagulation with warfarin (a vitamin K antagonist) 
following ACS has significantly reduced death and recurrent events compared to placebo 
by 34% and 24% respectively (106). Compared to aspirin, warfarin offered a significant 
19% risk reduction in MACE following ACS at the expense of a significant 25% increase 
in risk of major bleeding, which greatly limited its routine use (107).  
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Rivaroxaban is an oral, directly-acting factor Xa inhibitor (108). Factor Xa is the 
penultimate step in the coagulation pathway, which culminates in the production of 
thrombin and fibrin clot formation. It has predictable pharmacokinetics and does not 
usually require monitoring. Anticoagulation (with 20 mg daily) with rivaroxaban in atrial 
fibrillation (AF) patients, yielded similar efficacy in terms of stroke prevention to 
warfarin with comparable rates of major bleeding (109).  
Low-dose rivaroxaban (2.5 mg twice daily and 5 mg twice daily) has been tested in ACS 
in the ATLAS ACS2-TIMI 51 trial (9). Investigators randomised moderate- to high-risk 
ACS patients (after stabilisation following the acute event including revascularisation if 
needed) to placebo, rivaroxaban 2.5 mg twice daily or 5 mg twice daily. This was in 
addition to standard medical therapy that included DAPT (aspirin + 
clopidogrel/ticlopidine). MACE was reduced with rivaroxaban compared to placebo 
(8.9% vs. 10.7%, p = 0.008): a reduction driven by recurrent MI and cardiovascular 
mortality. Non-CABG major bleeding events were significantly higher with rivaroxaban 
(2.1% vs. 0.6%, p < 0.001). There was a trend towards less bleeding events with the 
lower dose (2.5 mg) compared to the higher dose (5 mg) with improved all-cause 
mortality with the lower-dose rivaroxaban as compared to placebo (2.9% vs. 4.5%, p = 
0.002).  
Apixaban is another directly-acting factor Xa inhibitor. Anticoagulation with apixaban 
(5 mg twice daily) is superior to warfarin in reducing stroke in AF patients (110). The 
same dose (5 mg twice daily) was tested in ACS patients in the APPRAISE-2 trial (111) 
against placebo on top of standard medical therapy including DAPT (aspirin + 
clopidogrel). Due to increased bleeding events including fatal and intracranial bleeds 
with no clear benefit, the trial was stopped prematurely.  
These two trials indicate that a small dose of anticoagulant might have a role to play in 
secondary prevention. Currently the more potent P2Y12 inhibitors (ticagrelor/prasugrel) 
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are preferred to clopidogrel in ACS and adding anticoagulants to these is unlikely to be 
tolerated in all patients. However, the residual ischaemic risk despite ticagrelor/prasugrel 
treatment might indicate that a selected cohort of patients would benefit from further 
optimisation of antithrombotic therapy. Markers of increased thrombotic risk might be 
best placed to help identify patients who are suitable for more intensive therapy. 
In this section, I will discuss possible markers that indicate increased propensity to 
thrombosis and how they correlate with clinical outcome.  
1.6 Potential markers of increased thrombotic risk  
1.6.1 Coagulation factors  
As most clotting factors are implicated in arterial thrombosis, it is no surprise that 
patients with bleeding disorders such as haemophilia A (Factor VIII deficiency) and B 
(Factor IX deficiency) have some protection against MI (112, 113). Even mild factor 
VIII and IX deficiencies in relatives of haemophilia patients conferred some 
cardiovascular mortality benefit (114). Contrary to this, factor XI deficiency showed no 
protection against ACS (115) whereas high factor IX and XI levels have been identified 
as possible predictors of MI (116). Factor VIII was also demonstrated to be elevated in 
ACS patients (117). Although this suggests that these factors may play an important role 
in thrombus formation in ACS, high levels of factor VIII have not been clearly associated 
with increased risk of ACS (118). Most of these observations originate from relatively 
small epidemiological studies and therefore it is difficult to reach a firm conclusion 
regarding the prognostic value of these measurements. Furthermore, clot formation is 
complex and involves multiple interactions between many different proteins and cells. 
Therefore, levels of individual clotting factors may not be successful in identifying 
patients with increased risk.    
However, fibrinogen is the only factor that has been consistently shown to predict risk 
of arterial thrombosis irrespective of its relationship with conventional risk factors.  
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Fibrinogen molecules consist of 2 pairs of 3 non-identical aminopeptide chains Aα, Bβ 
and g (Figure 1-4).  These chains are connected through disulfide bonds. The N termini 
form the central E region whilst the carboxy termini of Bβ and g chains form the D 
regions (119). Thrombin cleaves fibrinopeptide A (FpA) and fibrinopeptide B (FpB) in 
the E nodule, exposing the positively charged A and B sites. A and B sites bond with the 
negatively charged a and b sites in the D region of other fibrin monomers to form 
protofibrils that further aggregate to form fibrin fibres (32, 120, 121). The arterial clot 
consists of a network of fibrin fibres with embedded platelet aggregates, red blood cells 
and leukocytes. 
 
Figure 1-4: Schematic drawing of the fibrinogen molecule 
3 different chains named Aα, Bβ and g. N termini of the chains form the central E domain. 
Carboxy termini of Bβ and g chain form the D domain. Thrombin acts by cleaving 
fibrinopeptide A (FpA) and fibrinopeptide B (FpB) in the E domain exposing the 
positively charged sites named A and B and forming fibrin monomer. Both A and B bind 
to negatively charged a and b sites respectively in the D domain of another fibrin 
monomer forming protofibrils. Protofibrils aggregating together form fibrin fibres. 
 
Fibrinogen levels are strongly related to the risk of ACS. The Fibrinogen Studies 
Collaboration have completed an individual participant meta-analysis of 31 studies 
involving over 150,000 healthy participants showing an adjusted hazard ratio for CAD 
of 2.42 (95% CI, 2.24 – 2.46) for every 1 g/L increase in fibrinogen levels (122).  
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In patients with CAD, high fibrinogen levels were related to the extent of disease and 
also found to be an independent predictor of worse outcome (123, 124).  
Both fibrinogen and D-dimer were found in tissue samples of atherosclerotic plaques, 
raising the hypothesis that fibrinogen plays a role in the pathogenesis of atherosclerosis 
through the formation of mural thrombi in the vessel walls (125).  
 
1.6.2 Lysis markers  
Thrombotic occlusion of a coronary artery could be viewed as failure of the protective 
fibrinolytic activity to effectively lyse the clot. In patients presenting with STEMI, 
approximately 15 – 20 % have spontaneous reperfusion (126, 127). This probably 
indicates an efficient fibrinolytic activity, which translates into better outcomes.  
Interpreting the significance of blood levels of lysis markers is challenging. Intuitively, 
it could be argued that greater levels of tPA and D-dimer reflect efficient lysis, which 
might be beneficial. However, thrombosis will inevitably lead to tPA activation and 
subsequently D-dimer release and therefore these could be indirect markers of increased 
thrombotic burden. Similar analogy could apply to levels of inhibiting factors such as 
TAFI, PAI-1 and a2-PI. Furthermore, these markers do not reflect the overall 
thrombolytic potential of the fibrin clot, which is influenced by interactions between 
multiple complex pathways.    
This might explain the conflicting data in the literature when it comes to the prognostic 
value of these different markers in predicting the incidence of CAD or in the context of 
ACS (128-136). 
1.6.3 Fibrin clot network  
The fibrin network forms the skeleton of blood clots and the structure of fibrin clots can 
determine stability and susceptibility to lysis.  
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Fibrin clots in patients with advanced and premature CAD have demonstrated 
“unfavourable” properties of increased fibrin density with thinner fibres that are more 
difficult to lyse (131, 137, 138). ACS patients also display similar unfavourable fibrin 
characteristics (139-141). Patients with DM, CKD and PAD are at higher risk of 
thrombotic complications (78, 142) and prothrombotic changes in fibrin clot networks 
might be one mechanism for the increased risk (143).  
Quantitative and qualitative changes in coagulation, lysis and other plasma proteins can 
influence fibrin clot properties. For instance, fibrinogen levels might affect fibrin clot 
density (138) and increased levels in animal models have resulted in more rapid 
thrombosis and resistance to lysis (144). High concentrations of prothrombin and 
thrombin can also result in more compact and thinner fibrin fibres (145). At fibre level, 
thick fibres are more difficult to lyse; however, fibrin clots made of densely packed thin 
fibres are less permeable to lytic protein and therefore take longer to lyse (146).  
Post-translational modifications to the fibrinogen molecule can also lead to lysis 
inefficiency. Increased fibrinogen oxidation is one mechanism for reduced lysis potential 
(147). Protein glycation, particularly glycation of fibrinogen lysine residues as a result 
of hyperglycaemia associated with DM, inhibits plasmin generation and results in 
prolonged lysis (148).  
Factor XIII also plays an important role in fibrin clot stability. Following activation by 
thrombin, it promotes cross-linking of fibrin fibres (α and g chains) and incorporation of 
α2-PI to fibrin clots, leading to compact clots that resist lysis (149-151). Activated factor 
XII also contributes to fibrin clot density and stability by binding the N termini of 
fibrinogen molecules (152).  
 33 
As discussed earlier, PAI-1 limits tPA activity and therefore elevated levels might 
contribute to inefficient lysis. Moreover, TAFI breaks the feedback cycle between fibrin 
formation and activation of plasmin and therefore limits lysis potential.  
Inflammation unfavourably modulates fibrin clot characteristics (138, 153). 
Incorporating complement C3 in fibrin clots could be one mechanism for prolonged lysis, 
an effect that is enhanced in patients with DM (132). Factor XIII might be responsible 
for the incorporation of complement C3 into the fibrin clot (154).  
Common genetic variations of both fibrinogen and factor XIII also determine fibrin clot 
structure (155, 156). A twin study has demonstrated a significant 40% heritability in the 
overall fibrin clot structure (157).  
Studying fibrin clot formation and lysis potential appears attractive as it offers a global 
assessment of thrombus formation. It has the potential to give us a holistic assessment of 
complex and dynamic processes, exploring the qualities of fibrin clot as opposed to 
measuring different factors leading to fibrin clot formation.  
1.6.4 Tissue factor and platelet-monocyte aggregates 
TF ignites the coagulation cascade at the site of plaque rupture by binding to and 
activating factor VII. Although most TF is tissue-bound, circulating TF can also be 
measured in plasma. Patients with CAD and ACS have increased levels of TF (158, 159). 
A few studies have demonstrated a positive relationship between rising levels of 
circulating TF and worse outcomes following ACS. In a study involving 523 ACS 
patients followed up for over 2 years, cardiovascular death was significantly higher in 
the highest quartile of TF (HR 2.06, CI 1.24-3.45, p = 0.006) (160). Other smaller studies 
reached similar conclusions (161, 162). Although the functional capacity of circulating 
TF is not clear, higher levels might indicate more extensive disease and increased 
thrombotic potential.  
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Activated platelets express the adhesion molecule CD62P (P-selectin) through which 
they bind to monocytes, thus forming platelet-monocyte aggregates (PMAs). PMAs are 
found in stable CAD but levels significantly increase in ACS (163, 164). TF is also 
expressed on PMAs, potentially increasing thrombotic potential in CAD (165).  
1.6.5 Von Willebrand Factor  
vWF is a glycoprotein predominantly produced by endothelial cells (166). It promotes 
platelet adhesion and activation at the site of vessel injury. It also acts as a carrier to 
clotting factor VIII, protecting it from deactivation by protein C (167). Therefore, vWF 
can be a thrombotic marker as well as a marker of endothelial dysfunction (168).  
Traditional CAD risk factors have been associated with increased levels of vWF (169-
172), likely reflecting the relationship with endothelial dysfunction. Consequently, any 
relationship observed between high vWF levels in healthy volunteers and incidence of 
CAD largely disappears after adjustment for other risk factors (173).  
Numerous other studies have demonstrated a stronger relationship between vWF levels 
and worse outcome in CAD patients. In a study where 2960 stable CAD patients were 
followed up for 2 years, patients with recurrent coronary events tended to have 
marginally higher vWF levels than those with no recurrent events and vWF levels were 
strongly related to the extent of CAD (174). In another study, amongst 1212 ACS 
patients, patients with recurrent events had marginally but significantly higher vWF 
levels compared to a control group matched for age and sex (86). Similar signals were 
observed in other studies, indicating increased risk with higher levels of vWF (175-178). 
However, they were all relatively small epidemiological studies.  
Therapeutic interventions to target vWF have been developed (179). However, upstream 
inhibition of both coagulation arms is likely to be risky. For instance, combining a high 
dose anticoagulant with dual antiplatelet therapy resulted in unacceptable increase in 
major bleeding risk (111). Concerns regarding increased risk of bleeding and the 
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availability of treatments targeting specific pathways are likely to hinder the success of 
such treatment strategies.  
1.7 Inflammatory markers  
 
1.7.1 Leukocytes 
A relationship between elevated leukocytes and CAD is well established. Increasing 
levels of leukocytes translate into marginal increase in risk but likely through the 
association with traditional risk factors (180).  
As discussed earlier, inflammation contributes to the increased thrombotic risk. 
Leukocytes appear to play a critical role in thrombotic risk modulation. Under normal 
circumstances, leukocytes exert an anti-thrombotic effect by expressing endothelial 
protein C receptor (181), thrombomodulin (182) and TFPI (183).  
Once activated, as could happen when PMAs form, their action reverses to a pro-
thrombotic effect by producing coagulation factors. Neutrophils primarily produce 
cathepsin G and elastase (184). These are serine proteases that can activate factors V, 
VIII and X as well as inactivating antithrombotic factors (185-188).  
Activated neutrophils also secrete nuclear material (chromatins) that form neutrophil 
extracellular traps (NETs). NETs offer a platform for pro-thrombotic factors to 
accumulate and can activate factors XI and XII (189). Elevated markers of NETs have 
been associated with severe CAD (190).  
Monocytes also express TF and have been identified in atherosclerotic plaques (191, 
192). There are three different subsets of monocytes: classical (CD14++/CD16-), 
intermediate (CD14++/CD16+) and non-classical (CD14+/CD16++). In 951 patients 
undergoing elective PCI, levels of intermediate monocytes independently predicted 
MACE (193).  
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1.7.2 C-Reactive Protein and cytokines 
CRP is an acute phase reactant protein, produced primarily from hepatocytes in response 
to IL6. It is a marker commonly used to detect acute or chronic inflammatory processes. 
CRP promotes the complement pathway and macrophage phagocytosis of apoptotic cells 
(194).  
In a meta-analysis of over 160,000 participants, high CRP levels were independently 
related to CAD (Risk ratio 1.44; CI 1.32-1.57) and vascular mortality (Risk ratio 1.55; 
CI 1.37-1.76) (195).  
Upstream of CRP in the inflammatory cascade are cytokines such as IL6, TNF-α and 
IL1.  
A recent meta-analysis involving over 29 prospective studies showed a significant 
relationship between different cytokines, including IL6, TNF-α and IL18, and the risk of 
CAD (196).   
Of particular interest is IL6, with some studies suggesting a causal relationship with 
CAD. Most convincing of all are the Mendelian genetic studies: certain polymorphisms 
of alleles implicated in IL6 and its receptor signalling pathways resulted in lower CRP 
levels and conferred some lifetime cardiovascular protection (197). This is in contrast to 
CRP Mendelian randomisation studies that did not indicate a causal relationship between 
alleles implicated in high CRP levels and incidence of CAD (198).  
Growth differentiation factor (GDF) 15 belongs to the family of TGFb proteins. It has 
emerged as a cardio-protective protein in cases of induced myocardial ischaemia, 
limiting macrophage adhesion to endothelial cells and reducing the inflammatory 
response (199, 200). It has been shown to be a predictor of recurrent events following 
ACS (201, 202). Intriguingly, high levels of GDF-15 were shown to be an independent 
predictor of major bleeding in ACS patients (202). The exact mechanisms for this are 
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unclear but it might be a combination of associations with other risk factors and possible 
inhibition of platelet integrin receptors (203).  
1.8 Future perspectives and discussion 
 
The driving forces behind recurrent ischaemic events are complex and require careful 
consideration. In the PLATO trial (5), 5.8% of patients receiving ticagrelor suffered 
recurrent MI and about 9% of patients with raised inflammatory markers had recurrent 
MI or cardiovascular death in the first year (4). This is despite potent and consistent 
P2Y12 inhibition levels achieved with ticagrelor (204-207). The mechanisms leading to 
these ischaemic events are difficult to pin down but some possible explanations might be 
adherence to antiplatelet therapy, a prothrombotic state or increased bleeding events. 
Higher levels of inflammatory markers at the time of ACS presentation are associated 
with higher risk of recurrent ischaemic events and it is possible that a “prothrombotic 
state” is partially responsible for this observation. Further studies are needed to shed 
some light on the mechanisms leading to recurrent events and potentially identify 
patients who might benefit from intensive treatment, thus mitigating ischaemic risk 
without increasing bleeding events. Balancing risks of ischaemia and bleeding is 
important as there is a clear relationship between major bleeding events and worse 
outcome (208). In a meta-analysis of PCI studies involving over 500,000 patients, major 
periprocedural bleeding was independently related to risk of mortality (Odds ratio 3.31; 
CI 2.86 – 3.82) and also independently related to major adverse cardiovascular events 
(OR 3.89; CI 3.26 - 4.64) (209). It is likely that many factors contribute to these 
observations, including a tendency to discontinue antithrombotic treatment, increased 
inflammatory state associated with bleeding (210) and possibly also increased 
erythropoietin secretion (211, 212).  
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The availability of potent and consistent P2Y12 inhibitors have led to question whether 
there is any scope for additional therapy. Some have questioned the role of aspirin (213). 
Recently, ticagrelor compared to aspirin failed to reduce cardiovascular events in both 
stroke and PAD patients (214, 215). These surprising findings indicate that P2Y12 
inhibition alone is unlikely to offer sufficient protection in high-risk ACS patients. 
Moreover, although platelets are optimally inhibited with contemporary treatment with 
aspirin and ticagrelor, the protein coagulation arm remains unaffected. Trials will be 
needed to choose the optimal antiplatelet regimen in addition to anticoagulant therapy. 
GEMINI-ACS study showed low-dose rivaroxaban to have similar safety profile to 
aspirin when combined with P2Y12 inhibition post ACS (216).  Ongoing trials, including 
Global Leaders (213) and TWILIGHT (9), are investigating ticagrelor monotherapy after 
PCI.  
Targeting the inflammatory pathway might also play a role in the future. Anakinra (IL1 
receptor antagonist) successfully reduced inflammatory markers in ACS patients; 
however, pilot data raised concerns regarding its safety (217). Strategies inhibiting 
upstream inflammatory pathways, such as lipoprotein-phospholipase A2 and p38 
mitogen-activated protein kinase (MAPK), have failed to improve outcomes and, in some 
cases, resulted in increased risk (218-220). These failures could indicate that 
inflammation is an important response to vascular injury and to some extent could be 
protective.  Moreover, inflammation is a physiological response to many illnesses and 
dampening this response could increase the risk of other conditions such as sepsis and 
malignancy. An ideal inflammatory target is therefore likely to be a specific pathway that 
is negatively implicated in and probably unique to atherosclerosis.  
Inhibiting IL1β with canakinumab in MI patients who have CRP levels > 2 mg/L has 
resulted in a modest but significant reduction in recurrent events but resulted in increased 
risk of fatal infections in the CANTOS trial (221). The benefit appeared greatest in those 
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who responded to treatment with a drop in CRP to < 2 mg/L (222). These interesting 
findings have opened the gate to new possibilities in managing high-risk ACS patients.  
Furthermore, epidemiological studies have identified potential triggers that are 
associated with ACS. As well as certain physical and emotional attributes, smoking and 
cocaine use, air pollution was identified as a major contributor at the population level 
(223). Public health interventions aiming at improving pollution levels, may therefore 
help improve outcomes following ACS (223).  
In conclusion, there remains a need to further optimise therapy in patients with ACS. 
Understanding some mechanisms behind recurrent events will guide further research to 
improve prognosis following ACS.  
1.9 Rationale 
As discussed above, mechanistic insights into recurrent events following ACS are needed 
to identify potential treatment targets that may improve prognosis. We have discussed 
how patients with high-risk conditions have dense fibrin clots with impaired lysis. We 
therefore hypothesize that adverse fibrin clot properties independently predict worse 
outcomes following ACS. Confirming inefficient lysis as a prognostic biomarker may 
aid clinicians to choose patients likely to benefit from additional therapy. 
Low-dose anticoagulation with rivaroxaban, in addition to aspirin and clopidogrel, 
successfully improved ischaemic outcomes following ACS (9). The ability of different 
anticoagulants, including rivaroxaban, to modulate fibrin clot formation and lysis will be 
explored. This may be a novel approach to assess treatment effects, when necessary, and 
may help us understand if additional anticoagulant therapy is a viable option to target 
fibrin clot lysis.  
We have also discussed the limitations of oral P2Y12 inhibitors in STEMI patients 
undergoing primary angioplasty. Delayed absorption could result in acute thrombotic 
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complications and strategies to deal with this issue are needed. We will explore a strategy 
of continuous anticoagulation with enoxaparin for 6 hours and study the 
pharmacodynamic effects of this regimen. The results of this study will guide future 
research. Furthermore, we will be able to understand how treatment with enoxaparin 
influences fibrin clot properties (ex-vivo).   
1.10 Aims 
• Study fibrin clot properties in ACS patients and explore the relationships between 
fibrin clot density/lysis potential and clinical characteristics and inflammatory 
markers.  
• Study the independent association between fibrin clot properties at hospital 
discharge and clinical outcomes in patients with ACS.  
• Explore whether studying fibrin clot properties in ACS patients with DM would 
yield additional prognostic value.  
• Study the variability of fibrin clot phenotype over time by comparing results of 
fibrin clot properties at hospital discharge and at 1-month follow-up as well as 
exploring how these properties change in relation to change in inflammatory 
markers.    
• Study the in-vitro effects of different concentrations of factor Xa inhibitors on 
fibrin clot properties as a novel approach to monitoring therapy and a possible 
approach to positively modulate fibrin clot structure.  
• Complete a clinical study (PENNY PCI) of the pharmacodynamic effects of a 
novel anticoagulant regimen (bolus enoxaparin + 6-hour infusion) in the context 
of primary PCI as a safe and inexpensive solution to the delayed absorption of 
oral P2Y12 inhibitors in the acute setting.  
1.11 Declaration 
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2 Chapter 2: Methods 
2.1 Establishing the association between fibrin clot properties and 
clinical outcomes following ACS 
2.1.1 Patient population and samples 
The PLATelet inhibition and patient Outcomes (PLATO) trial was an international multi-
centre, double-blind, RCT of ticagrelor compared with clopidogrel in 18,624 moderate- 
to high-risk ACS patients. The study design and results have previously been published 
(5, 224). Baseline patient characteristics, including medical and medication history, were 
recorded at baseline. Study visits were performed at 1, 3, 6, 9 and 12 months.  In the 
PLATO biomarker sub-study (225), a subset of 4,354 patients provided blood at hospital 
discharge, and 4,032 provided blood at 1-month follow-up. Hospital discharge samples 
were used in order to minimise the effects of anticoagulant therapy used as part of initial 
ACS management and 1-month samples were used in order to assess the effect of 
inflammation resolution on fibrin clots. Plasma was obtained from citrate-anticoagulated 
venous blood samples and stored initially at –20 °C prior to transfer to Uppsala Clinical 
Research Centre for storage at –80 °C. All study patients provided written informed 
consent according to a protocol approved by local research ethics committees at 
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participating centres. For our analyses, plasma samples were transferred to the University 
of Sheffield in freezer conditions and stored at –80 °C until analysis.  
To assess the relationship between fibrin clot properties and fibrinogen levels, we used 
37 stored plasma samples collected from a local ACS cohort at day 7 after the ACS event 
(207, 226). 
2.1.2 Fibrin clot assessment  
Human thrombin was obtained from Merck Biosciences (Calbiochem), recombinant tPA 
from Technoclone, calcium chloride dehydrate (CaCl2) and Tris from Fisher Scientific, 
and sodium chloride (NaCl) from Sigma Aldrich. High-throughput turbidimetric analysis 
was performed in flat-bottomed, polystyrene 96-well plates (Greiner) using a dedicated 
Multiskan FC (Thermo Scientific) plate reader. Permeation buffer solution (100 mM 
NaCl, 50 mM Tris, pH 7.4) was used for dilution. 25-µL of plasma (in duplicates) were 
mixed with 75 µL lysis mix and clots were formed by adding 50 µL activation mix (tPA 
83 ng/ml, CaCl2 7.5 mM, thrombin 0.03 U/ml; final concentrations). After shaking for 2 
seconds, plates were read at 340 nm every 12 seconds at 37 °C until lysis in all samples 
was achieved. Quality control samples were included in all plates. Although, there is no 
standard method for fibrin clot assessment, this method has previously been validated in 
multiple studies (139, 227-229). It is possible that the sensitivity of this assay is improved 
by reducing tPA concentrations, however, lower tPA concentrations may be insufficient 
to lyse all samples. Studying fibrin clot with different methodologies may be an ideal 
option but this approach is not possible when analysing > 4000 samples. Studied 
variables included lag time, lysis time (a measure of lysis potential) and maximum 
turbidity (turbidity refers to the scatter of light as a measure of fibrin clot density) (Figure 
2-1). All analyses were performed blinded to clinical outcomes and clinical 
characteristics.  
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Figure 2-1: Fibrin clot turbidimetric parameters 
Lysis time is measured from time of maximum turbidity till the time turbidity drops by 
50%. AU: arbitrary units. 
2.1.3 Determination of fibrinogen levels 
Reference plasma was obtained from Biomereux. Sodium acetate trihydrate and sodium 
barbital were obtained from Sigma Aldrich.  
KC10 clotting analyser was used for determination of fibrinogen levels using Clauss 
methodology: Plasma was diluted 1:10 with Veronal buffer solution (2.6 mM Sodium 
acetate trihydrate, 2.6 mM sodium barbital, pH 7.35) and thrombin was used to initiate 
clotting (5 U/ml; final concentration). When clotting was achieved in less than 7 seconds, 
plasma was further diluted 1:20.  
 
2.1.4 Statistical methods 
Cumulative rates of cardiovascular (CV) death or spontaneous MI (sMI) in the PLATO 
trial in patients in the highest quartile group of CRP levels were 12.3% compared to 7.3% 
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in the lowest quartile group (adjusted hazard ratio 0.57). We hypothesized fibrin clot 
properties to have a similar impact on this outcome measure. Allowing for events that 
occur pre-hospital discharge, we estimate a rate of 9% for the combined outcome 
measure of CV death or sMI in the highest quartile groups of lysis time and maximum 
turbidity. Including 4000 patient samples (1000 per quartile group) will give this study 
90% power to detect a 43% risk reduction between the highest and lowest quartile 
groups.  
Histograms were used to visually assess data distribution. Non-normally distributed data 
(all variables and biomarkers) were natural log-transformed. Baseline patient 
characteristics, medical history and biomarkers were compared across quartile groups of 
each of the fibrin variables. Continuous data are presented as medians and interquartile 
ranges (IQRs) and compared using Kruskal-Wallis tests. Categorical data are presented 
as numbers and percentages and compared using Chi-square tests. The primary outcome 
of interest was the composite of CV death and sMI. Secondary outcomes were CV death 
alone, sMI alone, all-cause mortality, stroke, definite or probable stent thrombosis 
according to Academic Research Consortium criteria, PLATO-defined major bleeding, 
and PLATO-defined major bleeding unrelated to coronary artery bypass graft surgery 
(CABG). Kaplan-Meier curves were derived to visually compare cumulative event rates 
across the four quartile groups of each of the fibrin clot variables. Cox proportional 
hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals 
(CIs). HRs are expressed per 50% increase in value when assessed as continuous 
variables or compared to the lowest quartile group when assessed as categorical 
variables. Two models were used for adjustment. Model 1 included randomized 
treatment, type of ACS, age, gender, body mass index (BMI), smoking history, 
hypertension (HTN), dyslipidaemia, DM, CKD and previous MI, congestive heart failure 
(CHF), revascularisation, ischaemic stroke or PAD. Model 2 included all variables in 
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model 1 (excluding CKD) and the following inflammatory and prognostic biomarkers: 
N-terminal pro B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin T, 
cystatin C, CRP, growth differentiation factor-15 (GDF-15) and white cell count (WCC). 
The choice of these variables is based on our knowledge of factors that have been related 
to clinical outcome in the PLATO cohort (202, 230-233). The assumptions of 
proportional hazards were assessed visually by calculating Schoenfeld residuals. To 
assess the prognostic value of fibrin clot properties, Harrell’s C-index was estimated and 
compared to a clinical predictive model (Model 1) with and without the addition of fibrin 
clot variables using likelihood ratio tests. The efficacy and safety of ticagrelor compared 
with clopidogrel according to fibrin clot properties was assessed using a Cox 
proportional hazards model that included transformed fibrin clot variables using 
restricted cubic splines and randomized treatment by fibrin clot variables interaction. 
Interaction analyses using restricted cubic splines have been performed to study the 
interaction between presentation, treatment strategy, treatment with low-molecular-
weight heparins and the prognostic value of fibrin clot parameters.  
Subgroup analysis of patients with DM was performed to explore the prognostic value 
of fibrin clot properties at hospital discharge following ACS in patients with DM. Due 
to the exploratory nature of this study, we did not adjust for multiple testing.  
Hospital discharge and 1-month fibrin clot properties were compared using Wilcoxon 
signed-rank tests. Spearman correlation and Bland-Altman plots were used to study the 
relationships between the two time-points. The relationship between change in fibrin clot 
properties and change in inflammatory biomarkers has also been assessed.   
All statistical analysis was performed using R statistics software (Version 3.3.2; R 
Foundation for Statistical Computing, Vienna, Austria). 
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2.2 Modulation of the fibrin clot network with different anticoagulants 
2.2.1 Reagents and fibrin clot assessment 
Rivaroxaban and apixaban were obtained from Cayman Chemical, fondaparinux from 
Aspen, enoxaparin from Sanofi Aventis, dimethyl sulfoxide (DMSO) from Sigma-
Aldrich and TF from Stago. 
Fibrin clot dynamics were assessed using the same validated turbidimetric assay 
described above (227, 228) but with TF to induce thrombosis. 25 µL of plasma (in 
duplicates) was mixed with 75 µL of the activation mix (83 ng/ml tPA, 1 pM TF, 17 mM 
CaCl2; final concentrations). Plates were maintained at 37°C and read every 30 seconds 
at 340 nm, until lysis of all samples. Clotting only assays were performed by excluding 
tPA in the activation mix. Variables included lag time, maximum turbidity and lysis time.  
2.2.2 Plasma samples 
Citrate-anticoagulated venous samples were collected from healthy volunteers and ACS 
patients (1-month post event) as per protocols approved by the local ethics committee. 
Blood was centrifuged at 3000 x g for 15 mins and plasma samples were obtained and 
stored at - 80° prior to analysis. Written informed consent was obtained from all 
individuals donating blood for these studies.  
Rivaroxaban and apixaban were dissolved in DMSO, further diluted with permeation 
buffer and mixed with plasma (1:10) to achieve final concentrations of 1 µg/L, 3 µg/L, 
10 µg/L, 33 µg/L, 100 µg/L, 330 µg/L and 1000 µg/L with final concentrations of DMSO 
of 1/1000. Fondaparinux was diluted with permeation buffer and mixed with plasma 
(1:10) to achieve final concentrations of 33 µg/L, 100 µg/L, 330 µg/L, 1000 µg/L and 
10,000 µg/L. For clotting and lysis assays, fondaparinux was mixed with plasma (2:10) 
to achieve a final concentration of 500 µg/L. Enoxaparin was also diluted with 
permeation buffer and mixed with plasma (1:10), achieving final concentrations of (0.5 
IU/ml and 1 IU/ml). Change in fibrin clot parameters was compared to control plasma 
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diluted with permeation buffer ± DMSO by the same ratios. These concentrations cover 
the clinically relevant range for these anticoagulants as summarised in table 2-1.  
2.2.3 Statistical analysis 
Data is presented as mean ± standard error of the mean (SEM). Paired/unpaired t tests 
and repeated measures analysis of variance (ANOVA) were used to determine 
significance of effect as appropriate. Multiple comparisons against control samples were 
performed using Dunnett’s multiple comparison tests. Significance levels were drawn at 
p < 0.05. All statistical analyses were performed on GraphPad Prism 7. 
 
Table 2-1: Summary of pharmacokinetic data for fondaparinux, rivaroxaban and 
apixaban 
 
Anticoagulant Dose Cmax µg/L Ctrough µg/L Reference 
Fondaparinux 2.5 mg OD 530 (200-830)a 
 
210 (80-530)a (234, 235) 
Fondaparinux 5 – 7.5 – 10 mg 
OD (weight 
adjusted) 
(1200-1260)b  (460-620)b (236, 237) 
Rivaroxaban 2.5 mg BD 47 (28-70)a 17 (6-37)a (238) 
Rivaroxaban 20 mg OD 249 (184-343)c 44 (12-137)c (239) 
Apixaban 2.5 mg BD 62.3d 21d (240) 
Apixaban 5 mg BD 128.5d 49.6d (240) 
All values represent steady-level state. a Medians (5th – 95th percentile range). b Range of 
means. c Geometric means (5th – 95th percentile range). d Geometric means. OD: once 
daily; BD: twice daily.  
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2.3 Prolonged ENoxapariN in primarY Percutaneous Coronary 
Intervention: PENNY PCI trial 
 
2.3.1 Trial design 
This is a single-centre, single-arm pharmacodynamic pilot study of an intra-arterial (IA) 
bolus of enoxaparin (0.75 mg/kg) followed by an intravenous (IV) infusion of enoxaparin 
(0.75 mg/kg) over 6 hours in STEMI patients undergoing primary percutaneous coronary 
intervention (PPCI). We planned to stop the infusion at 3 hours in patients with 
significant renal impairment, defined by an estimated glomerular filtration rate (eGFR) 
of < 30 ml/hr (cumulative dose of 1.125 mg/kg).  
2.3.2 Study population 
We have recruited 20 patients presenting acutely with STEMI according to the following 
inclusion and exclusion criteria:  
Inclusion criteria 
1. Age ≥ 18 
2. Confirmation of the diagnosis of STEMI on the basis of a classical history, ECG 
changes and angiographic findings 
3. Pre-treatment with either ticagrelor or prasugrel 
4. Intention to proceed with PPCI  
5. Feasibility to obtain informed verbal consent pre PPCI 
Exclusion criteria 
1. Active bleeding that cannot be controlled by local measures 
2. Pregnant patients 
3. Patients with end-stage renal failure requiring renal replacement therapy 
4. Known thrombocytopenia (platelet count < 100,000/µL) 
5. Known history of intracranial haemorrhage 
6. Known current treatment with oral anticoagulants 
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7. Known history of major surgery or trauma or history of GI/GU haemorrhage 
within the last month 
8. Known intracranial malignancy or aneurysm 
9. Known allergy to enoxaparin 
10. Known hypersensitivity to benzylalcohol 
11. Patients with acute bacterial endocarditis 
12. Active gastric or duodenal ulceration 
13. Inability to easily understand verbal information given in English for any reason 
14. Inability to give informed consent due to either temporary or permanent mental 
incapacity 
15. Current participation, or participation within the last month, in an interventional 
clinical trial. 
2.3.3 Study procedures 
Patients admitted to the catheter laboratory or coronary care unit with STEMI and 
accepted for PPCI were screened.  Figure 2-2 summarises the study procedures. 
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Figure 2-2: PENNY PCI flow chart 
STEMI: ST-elevation myocardial infarction; PPCI: Primary percutaneous coronary 
intervention; eGFR: estimated glomerular filtration rate 
 
 
Blood samples for pharmacodynamic assessment were collected at the following 
timepoints:  
1. Timepoint 1 (T1) prior to anticoagulation – at the start of PPCI procedure.   
2. Timepoint 2 (T2) at the end of PPCI.  
3. Timepoint 3 (T3) 2-3 hours from the start of enoxaparin infusion.   
4. Timepoint 4 (T4) at the end of enoxaparin infusion.  
As PPCI is time-critical and delay in treatment can be detrimental to clinical outcome, 
informed verbal consent using an abbreviated patient information sheet was obtained 
prior to enrolment followed by informed written consent as soon as possible after PPCI. 
The consent process was performed by a qualified medical practitioner according to the 
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principles of Good Clinical Practice (GCP) and the declaration of Helsinki. Following 
consent, details of patient participation were sent to their general practitioner. 
Clinical outcomes and adverse events were determined at least 14 hours after initiation 
of the enoxaparin regimen. The half-life of enoxaparin is 1.5-2 hours when given 
intravenously to patients undergoing PCI (12) and, therefore, adverse events related to 
the study medication are unlikely to arise beyond 14 hours.  
Concurrent treatment with unfractionated heparin, bivalirudin, fondaparinux or 
glycoprotein IIb/IIIa inhibitors (GPIs) was prohibited. If GPI was used for bailout 
indications or to deal with thrombotic complications, enoxaparin infusion was to be 
stopped.  
2.3.4 Study objectives 
Primary objective 
The primary objective was to assess anti-Xa activity (IU/ml) at the three time-points after 
initiation of enoxaparin.  
Secondary objectives 
Secondary objectives were to assess the following: 
1. Fibrin clot properties (lag time, lysis time and maximum turbidity) at each of the 
timepoints.  
2. Clotting times and clot firmness as determined by thromboelastometry at each of 
the timepoints.   
3. Platelet P2Y12 % inhibition and Platelet Reactivity Units determined by 
VerifyNow P2Y12 assay at each of the timepoints.   
4. Rates of safety and efficacy events (any bleeding and acute stent thrombosis 
events) in order to obtain pilot data for guiding further studies.  
2.3.5 Laboratory analyses 
Anti-Xa levels were determined using the commercially-available Coamatic kit 
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(Chromogenix) and Sysmex CS-5100 analyser (241). Fibrin clot properties were 
determined using the same methodology described in 2.2.2.1 but with 10 pM TF (final 
concentration). Clotting times and clot firmness in whole blood was determined using 
thromboelastometry (ROTEM) with intem-S (Tem Innovations) reagents. P2Y12 
inhibition was determined using the VerifyNow analyser and P2Y12 assay cartridges at 
least 20 mins post-sampling, as per manufacturer’s instructions.     
2.3.6 Sample size and statistical methods 
Since this is a novel regimen, a formal sample size calculation was not possible prior to 
the start of the study. Following determination of anti-Xa levels at the end of PPCI, we 
have determined that we have >90% power to detect at least 25% drop in anti-Xa levels 
throughout the infusion. This was based on one-way ANOVA test.  
Continuous data are presented as mean ± SEM or median (interquartile range) as 
appropriate. Categorical data are presented as numbers and proportions. One-way 
ANOVA with Dunnett’s multiple comparison tests were used for assessment of 
continuous variable. Amongst opiate-treated patients, two-way ANOVA was used to 
assess the interaction between P2Y12 inhibition and antiemetic treatment. Results with 
P-values < 0.05 were considered statistically significant. Statistical analyses were 
performed using GraphPad Prism 7 for Mac OS X.  
2.3.7 Trial organisation 
This trial has been sponsored by Sheffield Teaching Hospitals NHS Foundation Trust 
and managed by the Cardiovascular Research Unit, University of Sheffield. Data was 
recorded using dedicated case report forms (Appendix) and subsequently transferred to 
an electronic database for analysis and archiving purposes.   
An independent data monitoring committee (DMC) reviewed data on safety and adverse 
events after the 10th patient had been recruited and at the end of the study.  
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2.3.8 Ethical considerations 
The study has been conducted according to European Union Clinical Trials regulations. 
The study protocol has been approved by the UK Medicines and Healthcare Products 
Regulatory Agency (MHRA) and the local research ethics committee (17/YH/0103). 
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3 Chapter 3: Fibrin Clot Properties Independently Predict Adverse 
Clinical Outcome Following Acute Coronary Syndrome: A 
PLATO Substudy  
Publications and abstracts arising from this chapter:  
1) The abstract has been presented at the American Heart Association 2017 
conference in Anaheim, California.  
2) Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Bertilsson M, 
Himmelmann A, Ajjan R, Storey RF. Fibrin clot properties independently predict 
adverse clinical outcome following acute coronary syndrome: A PLATO 
Substudy. European Heart Journal 2018;39:1078-85.  
Inclusion of this research in this thesis does not violate copyright agreements and is in 
agreement with co-authors.  
3.1 Abstract 
Introduction: Compact fibrin clots that resist lysis have been implicated in thrombotic 
conditions but large outcome studies are lacking. We investigated fibrin clot properties 
in a longitudinal study of patients with ACS.  
Methods: Plasma samples were collected at hospital discharge from 4,354 ACS patients 
randomized to clopidogrel or ticagrelor in the PLATO trial. A validated turbidimetric 
assay was employed to study plasma clot lysis time (a measure of fibrinolytic efficiency) 
and maximum turbidity (a measure of clot density). One-year rates of cardiovascular 
(CV) death, spontaneous myocardial infarction (sMI) and PLATO-defined major 
bleeding events were assessed after sample collection. Hazard ratios (HR) were 
determined using Cox proportional analysis. 
Results: After adjusting for CV risk factors, each 50% increase in lysis time was 
associated with CV death/sMI (HR 1.17; 95% CI 1.05-1.31; P<0.01) and CV death alone 
(HR 1.36; 1.17–1.59; P<0.001). Similarly, each 50% increase in maximum turbidity was 
associated with increased risk of CV death (HR 1.24; 1.03–1.50; p = 0.024). After 
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adjustment for other biomarkers (leukocyte count, high-sensitivity C-reactive protein, 
high-sensitivity troponin T, cystatin C, N-terminal pro B-type natriuretic peptide and 
growth differentiation factor-15), the association with CV death remained significant for 
lysis time (HR 1.15; 1.01–1.30; P=0.032) but not for maximum turbidity.  These 
associations were consistent regardless of randomized antiplatelet treatment (all 
interaction P > 0.05). Neither lysis time nor maximum turbidity was associated with 
major bleeding events.  
Conclusions: Fibrin clots that are resistant to lysis independently predict adverse 
outcome in ACS patients. Novel therapies targeting fibrin clot properties might be a new 
avenue for improving prognosis in patients with ACS. 
 
3.2 Background 
 
Recurrent events, including CV death, remain common following ACS. Intensive 
antithrombotic therapies, including potent P2Y12 inhibitors and the addition of low-dose 
anticoagulant therapy (rivaroxaban), have all resulted in improved outcomes but 
increased the risk of major bleeding events (5, 6, 9). 
There is marked overlap between risk factors for ischaemic and bleeding events (7, 242). 
Consequently, tailoring therapy to achieve the “sweet spot” of mitigating ischaemia 
whilst maintaining effective haemostasis is an ongoing challenge and readily-available 
biomarkers to aid the decision process are lacking. Spontaneous major bleeding events 
are associated with a similar prognosis to ischaemic events (243) and, in patients 
undergoing PCI, major bleeding events independently predict MACE (209).   
Following ACS, treatment includes aspirin and a P2Y12 inhibitor (244, 245). Although 
contemporary therapy effectively targets platelets (206, 246), around 20% of patients 
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suffer recurrent events within 12 months (7). This dual antiplatelet treatment strategy 
largely spares the protein arm of coagulation, which leads to fibrin formation.      
Patients with thrombotic conditions often demonstrate unfavourable fibrin clot structure 
(139-141). High-risk conditions, such as DM, CKD and PAD, have all shown 
associations with compact fibrin clots and resistance to fibrinolysis (143, 247, 248). 
However, the majority of studies in this area used a cross-sectional retrospective design 
and large-scale longitudinal studies are lacking.  We therefore aimed to study fibrin clot 
properties in plasma samples collected from ACS patients at hospital discharge and 
explore the relationship between those characteristics and clinical outcomes. 
3.3 Results 
3.3.1 The relationships between fibrin clot properties, clinical characteristics and 
biomarkers 
A total of 4,354 patients were included in this study. Tables 3-1 and 3-2 summarize the 
clinical characteristics and biomarkers across the four quartiles of both lysis time and 
maximum turbidity. The prevalence of DM, HTN, CKD and female sex significantly 
increased with increasing lysis time quartiles. Although the differences were not 
significant, the highest quartile of lysis time appeared to have the highest prevalence of 
PAD and CHF.  
Patients in the lowest lysis time quartile tended to be older but the absolute difference in 
mean age was small. Strong associations were also observed between lysis time and other 
biomarkers: with increasing quartiles, the levels of HsTnT, NT-proBNP, CRP and WCC 
increased. GDF-15 and cystatin-C levels were also highest in the highest quartile.  
Similar to lysis time, the prevalence of DM and CKD was highest in the highest quartile 
of maximum turbidity. There was a higher percentage of female patients in the lowest 
maximum turbidity quartile. The relationship between maximum turbidity and the other 
biomarkers was also pronounced (Table 3-2). 
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Neither lysis time nor maximum turbidity appeared to be affected by haemoglobin or 
haematocrit (Tables 3-1, 3-2).  
Maximum turbidity and lysis time had a modest correlation (Spearman correlation co-
efficient 0.375, P < 0.001) (Figure 3-1).  
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Table 3-1: Clinical characteristics and biomarkers across lysis time quartile groups 
Variables Lysis time (secs) quartile group P value 
Q1 (<564) 
n = 1098 
Q2 (564-696) 
n = 1108 
Q3 (696-888) 
n = 1066 
Q4 (>888) 
n = 1082 
Demographics and medical history 
Age (years) 63 (55 – 72) 61 (54 – 70) 61 (53 – 70) 61 (53 – 70) < 0.001 
Female 242 (22%) 318 (28.7%) 271 (25.4%) 442 (40.9%) < 0.001 
BMI (kg/m2) 27 (24.5-29.7) 27.3 (24.9-30.1) 27.8 (25.3-30.8) 28.6 (25.6-
31.8) 
< 0.001 
Current smoker 392 (35.7%) 450 (40.6%) 404 (37.9%) 349 (32.3%) < 0.001 
Hypertension 673 (61.3%) 717 (64.7%) 711 (66.7%) 764 (70.6%) < 0.001 
Hyperlipidaemia 453 (41.3%) 462 (41.7%) 456 (42.8%) 469 (43.3%) 0.744 
Diabetes mellitus 206 (18.8%) 221 (19.9%) 242 (22.7%) 305 (28.2%) < 0.001 
Previous MI 216 (19.7%) 215 (19.4%) 214 (20.1%) 201 (18.6%) 0.843 
Previous CHF 53 (4.8%) 59 (5.3%) 58 (5.4%) 79 (7.3%) 0.068 
Previous stroke 34 (3.1%) 42 (3.8%) 35 (3.3%) 40 (3.7%) 0.783 
PAD 62 (5.6%) 68 (6.1%) 63 (5.9%) 80 (7.4%) 0.345 
CKD 29 (2.6%) 42 (3.8%) 27 (2.5%) 49 (4.5%) 0.028 
Type of ACS 
 STE-ACS 504 (45.9%) 522 (47.1%) 510 (47.8%) 486 (44.9%) 0.536 
Biomarkers 
Troponin T (ng/L) 129 (35-453) 151 (37-511) 177 (46-582) 210 (47-755) < 0.001 
NTproBNP(pmol/L) 387 (119-992) 386 (129-1088) 389 (131-1033) 469 (139-1433) 0.009 
Cystatin C (mg/L) 0.80(0.65-0.97) 0.80 (0.66 – 0.96) 0.81(0.66– 0.97) 0.86(0.69-1.05) < 0.001 
GDF-15 (ng/L) 1503(1095-2058) 1446(1108-2092) 1509(1182-2064) 1584(115-2254) 0.003 
CRP (mg/L) 2.4 (1.1-5.8) 3.1 (1.4-7.6) 3.9 (1.8- 9.8) 5.2 (2.2-13.5) < 0.001 
WCC (x 109/L) 8.7 (6.9-10.9) 9.1 (7.3-11.4) 9.7 (7.8-11.9) 9.9 (7.8-12.5) < 0.001 
Haemoglobin (g/L) 141 (131-151) 142 (132-151) 142 (132-152) 141 (130-151) 0.144 
Haematocrit (L/L) 0.41(0.39-0.44) 0.42 (0.39-0.44) 0.42 (0.39-0.45) 0.42(0.38-0.44) 0.265 
Values are medians (IQRs) for continuous data and n (%) for categorical data. BMI: body mass index; MI: myocardial 
infarction; CHF: congestive heart failure; PAD: peripheral artery disease; CKD: chronic kidney disease; STE-ACS: 
ST-elevation acute coronary syndrome; NTproBNP: N-terminal pro b-type natriuretic peptide; GDF: growth 
differentiating factor; CRP: C-reactive protein; WCC: white cell count. P values calculated using Chi-square test 
(categorical variables) or Kruskal-Wallis test (continuous variables) 
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Table 3-2: Clinical characteristics and biomarkers across maximum turbidity quartile 
groups 
Variables Maximum turbidity (au) quartile group P value 
Q1 (≤ 0.38) 
n = 1091 
Q2 (0.38-0.5) 
n = 1089 
Q3 (0.5-0.62) 
n = 1085 
Q4 (>0.62) 
n = 1089 
Demographics and medical history 
Age, (years) 62 (54-71) 61 (53-70) 61 (54-70) 62 (54-70) 0.27 
Female 366 (33.5%) 334 (30.7%) 327 (30.1%) 246 (22.6%) < 0.001 
BMI (kg/m2) 27 (24.6-29.9) 27.8 (25.2-30.8) 27.8 (25.3-30.8) 28 (25.2-31.1) < 0.001 
Current smoker 358 (32.8%) 405 (37.2%) 409 (37.7%) 423 (38.8%) 0.02 
Hypertension 747 (68.5%) 690 (63.4%) 715 (65.9%) 713 (65.5%) 0.09 
Hyperlipidaemia 496 (45.5%) 492 (45.2%) 432 (39.8%) 420 (38.6%) < 0.001 
Diabetes mellitus 222 (20.3%) 225 (20.7%) 256 (23.6%) 271 (24.9%) 0.03 
Previous MI 259 (23.7%) 214 (19.7%) 194 (17.9%) 179 (16.4%) < 0.001 
Previous CHF 90 (8.2%) 54 (5.0%) 48 (4.4%) 57 (5.2%) < 0.001 
Previous stroke 43 (3.9%) 41 (3.8%) 29 (2.7%) 38 (3.5%) 0.38 
PAD 79 (7.2%) 63 (5.8%) 55 (5.1%) 76 (7%) 0.12 
   CKD 28 (2.6%) 37 (3.4%) 33 (3.0%) 49 (4.5%) 0.08 
Type of ACS 
 STE-ACS 392 (35.9%) 467 (42.9%) 553 (51%) 610 (56%) < 0001 
   Biomarkers 
Troponin T (ng/L) 90.6 (21.3 – 301) 129 (30.6 – 410) 163 (43.8 – 494) 375 (97.1 – 1161) < 0.001 
NTproBNP(pmol/L) 335 (124 – 867) 332.5 (111.8 – 904.2) 390.5 (117.8 – 989) 662 (191 – 1774) < 0.001 
Cystatin C (mg/L) 0.82 (0.66 –  0.99) 0.79 (0.65 – 0.96) 0.81 (0.66 – 0.98) 0.84 (0.68 – 1.02) 0.002 
GDF-15 (ng/L)  1447(1084-2007)    1417 (1065-1993)   1504 (1144-2076)   1692 (1243-2414) < 0.001 
CRP (mg/L) 2.4 (1.1 –  5.2) 2.7 (1.4 –  6.0) 3.9 (1.7 – 8.6) 6.8 (2.7 – 22) < 0.001 
WCC (*109/L) 8.2 (6.6 – 10.3) 8.9 (7.2 – 11.1) 9.7 (7.7 – 11.8) 10.7 (8.7 – 13.1) < 0.001 
Haemoglobin (g/L) 141 (130-150) 142 (132-151) 141 (131-150) 142 (132-152) 0.12 
Haematocrit (L/L) 0.42 (0.38-0.44) 0.42 (0.39-0.44) 0.41 (0.39-0.44) 0.42 (0.39-0.45) 0.05 
Values are medians (IQRs) for continuous data and n (%) for categorical data. AU: Arbitrary units; other 
abbreviations and P values calculations as per table 3-1.  
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3.3.2 Fibrin clot properties and inpatient treatment 
Proportions of patients treated with inpatient invasive treatment did not vary significantly 
across the four quartile groups of lysis time. However, significantly higher proportions 
of patients received invasive treatment in the highest quartile groups of maximum 
turbidity (Tables 3-3 and 3-4). 
A subset of 1637 patients received LMWH the day before sampling and 1229 patients 
continued to receive it on the day of sampling. However, the proportion of patients who 
received LMWH did not vary significantly across quartile groups of lysis time or 
maximum turbidity.  
Details of other inpatient treatments are summarised in tables 3-3 and 3-4.  
 
Figure 3-1: Relationship between maximum turbidity and lysis time 
Scatter plot of maximum turbidity and lysis time. AU: arbitrary units. N = 4354.  
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Table 3-3: Inpatient treatments across the four lysis time quartile groups 
Variables Lysis time (secs) quartile group P 
value Q1 (<564) 
n = 1098 
Q2 (564-696) 
n = 1108 
Q3 (696-888) 
n = 1066 
Q4 (>888) 
n = 1082 
Invasive 
treatment 
769 (70%) 793 (72%) 784 (74%) 742 (69%) 0.07 
Aspirin 1081 (99%) 1094 (99%) 1055 (99%) 1057 (98%) 0.085 
LMWH 608 (55%) 608 (55%) 593 (56%) 573 (53%) 0.59 
LMWH on day 
before sampling 
414 (38%) 403 (37%) 422 (40%) 398 (37%) 0.43 
LMWH on day of 
sampling 
311 (29%) 303 (28%) 321 (30%) 297 (28%) 0.47 
Fondaparinux 16 (1.5%) 17 (1.5%) 17 (1.6%) 24 (2.2%) 0.5 
ACE-I or ARB 954 (87%) 978 (88%) 925 (87%) 944 (87%) 0.71 
Statins 1051 (96%) 1060 (96%) 1004 (94%) 998 (92%) <0.001 
Beta blockers 959 (87%) 969 (88%) 929 (87%) 938 (87%) 0.95 
LMWH: low-molecular-weight heparins; ACE-I: angiotensin converting enzyme 
inhibitor; ARB: angiotensin II receptor blocker. P values calculated using Chi-square 
test.  
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Table 3-4: Inpatient treatments across the four maximum turbidity quartile groups 
Variables Maximum turbidity quartile P value 
Q1 (≤ 0.38) 
n = 1091 
Q2 (0.38-0.5) 
n = 1089 
Q3 (0.5-0.62) 
n = 1085 
Q4 (>0.62) 
n = 1089 
Invasive 
treatment 
637 (58.4%) 765 (70.2%) 820 (75.6%) 866 (79.5%) <0.001 
Aspirin 1077 (99%) 1074 (99%) 1065 (98%) 1071 (98%) 0.7 
LMWH 613 (56%) 613 (56%) 584 (54%) 572 (53%) 0.21 
LMWH on day 
before sampling 
436 (40.3%) 401 (37.1%) 408 (37.9%) 392 (36.3%) 0.26 
LMWH on day of 
sampling 
351 (32.4%) 303 (28%) 285 (26.5%) 293 (27.2%) 0.01 
Fondaparinux 15 (1.4%) 19 (1.7%) 19 (1.8%) 21 (1.9%) 0.79 
ACE-I or ARB 935 (86%) 946 (87%) 961 (89%) 959 (88%) 0.18 
Statins 1010 (93%) 1027 (94%) 1038 (96%) 1038 (95%) 0.007 
Beta blockers 
 
923 (85%) 957 (88%) 965 (89%) 950 (87%) 0.02 
LMWH: low-molecular-weight heparins; ACE-I: angiotensin converting enzyme 
inhibitor; ARB: angiotensin II receptor blocker. P values calculated using Chi-square 
test.  
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3.3.3 Fibrin clot properties and clinical outcome 
During follow-up, 145 patients (3.3%) died from any cause, 125 (2.9%) died from CV 
causes (‘CV death’), 183 (4.2%) had sMI and 41 (0.94%) had stroke. Only 38 (0.88%) 
had definite or probable stent thrombosis. PLATO-defined major bleeding occurred in 
256 patients (5.9%) with 96 (2.2%) having non-CABG-related major bleeding.  
Cumulative rates of the composite outcome of CV death and spontaneous MI were higher 
in the highest quartile groups of both lysis time and maximum turbidity compared with 
rates in the lowest quartile groups (Figure 3-2). This was primarily driven by higher rates 
of CV death in the highest quartile groups (Figure 3-3). After adjustment for CV risk 
factors (model 1), the highest quartile group of lysis time was associated with increased 
risk of CV death/spontaneous MI (HR 1.48; 95% CI 1.06-2.06; P = 0.027) and CV death 
alone (HR 1.92; 95 % CI 1.19-3.1; P < 0.001). As a continuous variable, each 50% 
increase in lysis time was associated with increased risk of CV death/spontaneous MI 
(HR 1.17; 95% CI 1.05-1.31; P = 0.006) and CV death alone (HR 1.36; 95% CI 1.17 – 
1.59; P < 0.001). This association remained significant for lysis time after adjustment for 
inflammatory and prognostic biomarkers. Similarly, each 50% increase in maximum 
turbidity was associated with CV death alone (HR 1.24; 95% CI 1.03 – 1.50; P = 0.024) 
but this association was no longer significant after adjustment for inflammatory and 
prognostic biomarkers. Findings for all-cause mortality were similar to those for CV 
death (Figure 3-4 and tables 3-5 and 3-6). 
There was no clear association with rates of stent thrombosis and stroke but event rates 
were low (Figures 3-6, 3-7). Neither lysis time nor maximum turbidity was able to predict 
major bleeding events (Tables 3-5, 3-6). Further characterisation of bleeding events is 
provided in tables 3-7 and 3-8.   
There was no significant impact of fibrin clot properties on the CV mortality reduction 
with ticagrelor compared with clopidogrel (interaction P values > 0.7) (Figure 3-5; Panels 
A,B). There was also no significant impact of fibrin clot properties on the association 
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between randomized treatment and major bleeding (Figure 3-5; Panels C,D). Similarly, 
the association between fibrin clot properties and CV death was present irrespective of 
subtype of ACS presentation (all interaction P > 0.4). The predictive value of fibrin clot 
parameters was not affected by LMWH treatment in the last 2 days, being consistent 
amongst those who received LMWH in the last two days compared with those who did 
not (Figure 3-8).  
The predictive value of fibrin clot lysis time was not affected by treatment strategy. 
However, the relationship between maximum turbidity and CV death appeared more 
pronounced in invasively-treated patients (Figure 3-9).  
3.3.4 Prognostic value of lysis time  
Model performance to predict the composite outcome of CV death/sMI significantly 
improved when lysis time was added to a clinical predictive model: C-index 0.67 (0.637 
- 0.703) for model 1 + lysis time vs. 0.665 (0.631 – 0.698) for model 1 only, P = 0.007. 
Prediction of CV death also significantly improved: C-index 0.7 (0.649 - 0.75) for model 
1 + lysis time vs. 0.69 (0.642 – 0.741) for model 1 only, P < 0.001. 
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Figure 3-2: Relationship between fibrin clot parameters and 1-year rates of CV 
death or sMI 
Kaplan-Meier curves for rates of the combined outcome of cardiovascular (CV) 
death/spontaneous myocardial infarction (MI) per quartile groups of lysis time (Panel A) 
and maximum turbidity (Panel B).  
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Figure 3-3: Relationship between fibrin clot parameters and 1-year rates of CV 
death 
Kaplan-Meier curves for 1-year rates of cardiovascular (CV) death per quartile groups 
of lysis time (Panel A) and maximum turbidity (Panel B).  
 
      
Figure 3-4: Relationship between fibrin clot parameters and 1-year all-cause 
mortality 
1-year rates of all-cause mortality in relation to lysis time (secs) (A) and maximum 
turbidity (AU) (B) transformed using restricted cubic splines. Shaded areas represent 
95% confidence intervals. Vertical lines indicate quartiles.    
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Figure 3-5: Relationship between fibrin clot parameters and 1-year rates of CV 
death or major bleeding according to randomized treatment group 
1-year rates of CV death (Panels A and B) or major bleeding (Panels C and D) in relation 
to maximum turbidity (AU) (Panels A and C) or lysis time (secs) (Panels B and D), 
transformed using restricted cubic splines, according to randomized treatment with 
clopidogrel (C, pink lines) or ticagrelor (T, blue lines). Shaded areas represent 95% 
confidence intervals. Vertical lines indicate quartiles limits.  
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Figure 3-6: Relationship between lysis time and 1-year rates of stent thrombosis (A) 
and ischaemic stroke (B) 
Kaplan-Meier curves for 1 year rates of definite or probable stent thrombosis (ST, panel 
A) and ischaemic stroke (Panel B) per quartile groups of lysis time 
 
 
Figure 3-7: Relationship between maximum turbidity and 1-year rates of stent 
thrombosis (A) and ischaemic stroke (B) 
Kaplan –Meier curves for 1 year rates of definite or probably stent thrombosis (ST, 
panel A) and ischaemic stroke (Panel B) per quartile groups of maximum turbidity 
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Figure 3-8: Relationship between fibrin clot parameters and 1-year rates of CV 
death according to treatment with LMWH within the last 2 days 
1-year rates of CV death in relation to lysis time (secs) (Panel A) and maximum turbidity 
(AU) (Panel B), transformed using restricted cubic splines, according to LMWH 
treatment in the last 2 days with LMWH (pink lines) or no LMWH (blue lines). Shaded 
areas represent 95% confidence intervals. Vertical lines indicate quartiles.  
 
Figure 3-9: Relationship between fibrin clot parameters and 1-year rates of CV 
death according to treatment strategy 
1-year rates of CV death in relation to lysis time (secs) (Panel A) and maximum turbidity 
(AU) (Panel B), transformed using restricted cubic splines, according to treatment 
strategy with invasive treatment (pink lines) or conservative treatment (blue lines). 
Shaded areas represent 95% confidence intervals. Vertical lines indicate quartiles.  
 
Table 3-5: Associations between lysis time and clinical outcomes 
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Event Model Continuous 
Lysis time 
P value Lysis time quartile groups (HR 
compared to the lowest quartile group) 
P value 
HR per 
50% 
increase 
Q2 
(564-696 
secs) 
Q3 
(696-888 
secs) 
Q4 
(>888 secs) 
CV 
death/ 
sMI 
Model 
1 
1.17 
(1.05-1.31) 
0.006* 0.92 
(0.64-1.32) 
1.09 
(0.77-1.55) 
1.48 
(1.06-2.06) 
0.027* 
Model 
2 
1.15 
(1.01-1.30) 
0.032* 0.88 (0.60-1.31) 
1.09 
(0.75-1.60) 
1.40 
(0.97-2.03) 0.088 
CV 
death 
Model 
1 
1.36 
(1.17-1.59) 
<0.001* 0.87 (0.50-1.51) 
0.79 
(0.45-1.39) 
1.92 
(1.19-3.10) <0.001* 
Model 
2 
1.20 
(1.01-1.42) 
0.042* 0.82 (0.46-1.47) 
0.79 
(0.43-1.44) 
1.44 
(0.85-2.45) 0.081 
All-
cause 
death 
Model 
1 
1.39 
(1.20-1.61) 
<0.001* 1.04 (0.62-1.77) 
1.24 
(0.74-2.06) 
2.24 
(1.40-3.57) 
0.001* 
Model 
2 
1.21 
(1.03-1.42) 
0.021* 0.95 (0.54-1.67) 
1.08 
(0.62-1.88) 
1.61 
(0.96-2.7) 
0.131 
sMI Model 
1 
1.08 
(0.94-1.25) 
0.287 0.83 (0.53-1.28) 
1.14 
(0.76-1.72) 
1.17 
(0.77-1.77) 0.36 
Model 
2 
1.12 
(0.96-1.31) 
0.15 0.80 (0.50-1.29) 
1.13 
(0.73-1.77) 
1.24 
(0.79-1.96) 0.29 
Major 
bleeding 
Model 
1 
1.09 
(0.96-1.23) 
0.18 1.03 (0.72-1.47) 
1.07 
(0.75-1.53) 
1.27 
(0.89-1.80) 0.56 
Model 
2 
1.07 
(0.94-1.23) 
0.31 1.04 (0.72-1.51) 
1.04 
(0.71-1.52) 
1.20 
(0.81-1.76) 0.81 
Estimates are HRs (95% CI).  Model 1 included adjustments for age, gender, BMI, Diabetes, Dyslipidemia, 
hypertension, chronic kidney disease (CKD), smoking, type of ACS, randomized treatment and previous 
myocardial infarction, revascularization, peripheral artery disease, congestive heart failure or 
cerebrovascular disease. Model 2 included adjustments as per model 1 (excluding CKD) and CRP, 
leukocyte count, cystatin C, NT-proBNP, high-sensitivity troponin T and GDF 15. CV: cardiovascular; 
sMI: spontaneous myocardial infarction. * indicates a statistically significant result.   
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Table 3-6: Associations between maximum turbidity and clinical outcomes 
Event Model Continuous 
maximum 
turbidity 
P value Maximum turbidity quartile groups 
(HR compared to the lowest quartile 
group) 
P 
value 
HR per 
50% 
increase 
Q2 (0.38-
0.5 au) 
Q3 (0.5-
0.62 au) 
Q4 (>0.62 
au) 
 
CV 
death/ 
sMI 
Model 1 1.13 
(0.99-1.27) 
0.06 1.3 (0.92-1.84) 
1.21 
(0.85-1.72) 
1.44 
(1.02-2.03) 0.2 
Model 2 1.01 
(0.88-1.16) 
0.87 1.25 (0.85-1.83) 
1.03 
(0.69-1.54) 
1.14 
(0.76-1.70) 0.64 
CV 
death 
Model 1 1.24 
(1.03-1.50) 
0.024* 1.21 (0.71-2.07) 
1.04 
(0.60-1.81) 
1.77 
(1.07-2.9) 0.08 
Model 2 0.96 
(0.79–1.16) 
0.65 1.04 (0.59-1.84) 
0.80 
(0.44-1.44) 
0.88 
(0.50-1.57) 0.8 
All-
cause 
death 
Model 1 1.22 
(1.03-1.46) 
0.024* 1.17 (0.71-1.92) 
1.10  
(0.67-1.83) 
1.71 
(1.07-2.72) 0.09 
Model 2 0.96 
(0.80-1.15) 
0.639 1 (0.58-1.71) 
0.85 
(0.49-1.48) 
0.93 
(0.54-1.59) 0.93 
sMI Model 1 1.08 
(0.93-1.25) 
0.332 1.25 (0.82-1.9) 
1.26 
(0.83-1.93) 
1.28 
(0.83-1.95) 0.63 
Model 2 1.06 
(0.89-1.27) 
0.483 1.27 (0.80-2.03) 
1.18 
(0.73-1.91) 
1.35 
(0.82-2.23) 0.64 
Major 
bleeding 
Model 1 0.99 
(0.87-1.12) 
0.89 0.87 (0.61-1.24) 
0.96 
(0.68-1.35) 
1 
(0.71-1.41) 0.86 
Model 2 0.93 
(0.81-1.07) 
0.324 0.8 (0.55-1.17) 
0.94 
(0.65-1.36) 
0.85 
(0.57-1.27) 0.68 
Estimates are HRs (95% CI). AU: arbitrary units; other abbreviations as per table 3-5.  Models 1 and 2 of 
adjustments as per table 3-5. * indicates a statistically significant result
 73 
Table 3-7: Bleeding events per lysis time quartile groups 
Type of bleeding All Lysis time (secs) quartile group 
Q1 (<564) 
n = 1098 
Q2 (564-
696) 
n = 1108 
Q3 (696-
888) 
n = 1066 
Q4 (>888) 
n = 1082 
Fatal 4 (0.09%) 1 (0.09%)   0 (0.00%) 2 (0.19%) 1 (0.09%) 
Major CABG-related 165 (3.82%) 41 (3.77%) 47 (4.28%) 38 (3.59%) 39 (3.64%) 
Major Non-CABG 
related 
96 (2.22%) 22 (2.02%) 17 (1.55%) 28 (2.64%) 29 (2.71%) 
Other major non-
CABG related 
11 (0.26%) 5 (0.46%) 0 (0.00%) 1 (0.09%) 5 (0.47%) 
Life-threatening/fatal  
non-CABG related  
16 (0.37%) 3 (0.28%) 3 (0.27%) 6 (0.57%) 4 (0.37%) 
Intracranial 5 (0.12 %) 1 (0.09%) 1 (0.09%) 2 (0.188%) 1 (0.09%) 
Minor 101 (2.34%) 21 (1.93%) 28 (2.55%) 23 (2.17%) 29 (2.71%) 
Major and minor 344 (7.97%) 79 (7.26%) 89 (8.11%) 82 (7.74%) 94 (8.77%) 
Major, minor and 
minimal      
381 (8.83%) 90 (8.27%) 96 (8.75%) 93 (8.78%) 102 (9.52%) 
For bleeding definitions, see appendix.  
 
 
Table 3-8: Bleeding events per maximum turbidity quartile groups 
Type of bleeding  All  Maximum turbidity (AU) quartile group 
Q1 (≤ 0.38) 
n = 1091 
Q2 (0.38-
0.5) 
n = 1089 
Q3 (0.5-
0.62) 
n = 1085 
Q4 (>0.62) 
n = 1089 
Fatal 4 (0.09 %) 0 (0.00 %) 1 (0.09%) 1 (0.09%) 2 (0.19%) 
Major CABG-related 165 (3.82%) 45 (4.17%) 39 (3.61%) 41 (3.80%) 40 (3.71%) 
Major non-CABG 
related  
96 (2.22%) 24 (2.22%) 18 (1.67%) 24 (2.22%) 30 (2.79%) 
Other major non-
CABG related 
11 (0.26%) 4 (0.37%) 2 (0.19%) 1 (0.09%) 4 (0.37%) 
Life-threatening/fatal 
non-CABG related   
16 (0.37%) 4 (0.37%) 4 (0.37%) 3 (0.28%) 5 (0.46%) 
Intracranial 5 (0.12%) 0 (0.00%) 2 (0.18%) 1 (0.09%) 2 (0.18%) 
Minor 101 (2.34%) 28 (2.59%) 23 (2.13%) 23 (2.13%) 27 (2.51%) 
Major and minor 344 (7.97%) 92 (8.52%) 76 (7.04%) 84 (7.79%) 92 (8.54%) 
Major, minor and 
minimal  
381 (8.83%) 100(9.26%) 87 (8.06%) 94 (8.71%) 100 (9.29%) 
For bleeding definitions, see appendix 
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3.3.5 Supplementary analysis of fibrin clot lag time 
Lag time was confounded by inpatient LMWH treatment: 76% of patients in the highest 
quartile group received LMWH, compared to only 38% in the lowest quartile group (p < 
0.001). Excluding patients who had received LMWH within 24 hours of blood sampling 
removed the imbalance in LMWH treatment between lag time quartile groups. Median 
(IQR) lag time was 348 (300-412) secs and there was no significant relationship between 
lag time measurements and clinical outcomes (P > 0.2 for all associations).  
3.3.6 Predictive value of fibrin clot properties in patients with diabetes mellitus 
972 patients had DM. Of those, 48 patients (4.9%) had CV death, 72 (7.4%) had sMI, 67 
(2.9%) had major bleeding and 21 (2.2%) had non CABG-related major bleeding. 
Cumulative rates of CV death or sMI increased with increasing levels of lysis time with 
no clear relationship between lysis time and major bleeding events (Figure 3-10). 
Similarly, rates of CV death or sMI increased with increasing levels of maximum 
turbidity. Rates of major bleeding events, however, appeared higher at lower levels of 
maximum turbidity (Figure 3-11).  
After adjustment for clinical characteristics and CV disease risk factors (model 1 except 
DM), each 50% increase in lysis time was associated with increased risk of CV death/sMI 
(HR 1.21; 95% CI 1.02-1.44; P = 0.026) and CV death alone (HR 1.38; 95% CI 1.08-
1.76; P = 0.01). Similarly, each 50% increase in maximum turbidity was associated with 
increased risk of CV death/sMI (HR 1.25; 95% CI 1.02-1.53; P=0.031) and CV death 
alone (HR 1.49; 95% CI 1.08-2.04; P = 0.014).  The trend for lower bleeding rates with 
lower maximum turbidity levels was not statistically significant (P = 0.15). 
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Figure 3-10: Relationship between fibrin clot lysis time and 1-year clinical outcomes 
in patients with diabetes mellitus 
1-year rates of CV death/sMI (A), CV death alone (B), sMI alone (C) and major bleeding 
(D) in relation to lysis time (secs) transformed using restricted cubic splines. Shaded 
areas represent 95% confidence intervals. Vertical lines indicate quartiles.    
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Figure 3-11: Relationship between fibrin clot maximum turbidity and 1-year 
clinical outcomes in patients with diabetes mellitus 
1-year rates of CV death/sMI (A), CV death alone (B), sMI alone (C) and major bleeding 
(D) in relation to maximum turbidity (AU) transformed using restricted cubic splines. 
Shaded areas represent 95% confidence intervals. Vertical lines indicate quartiles.  
 
3.3.7 Fibrinogen levels and fibrin clot properties 
 
37 plasma samples stored locally at Sheffield from ACS patients were used for this 
analysis. These samples were collected at day 7 post-ACS. Significant correlations were 
present between fibrinogen levels and maximum turbidity but there was no clear 
relationship between lysis time and fibrinogen levels (Figure 3-12). These results 
indicate that fibrinogen levels play a more pronounced role in fibrin clot density 
compared to lysis potential.  
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Figure 3-12: Correlations between fibrinogen levels and maximum turbidity (A) 
and lysis time (B) 
n=37, r value refers to Spearman’s correlation coefficient. 
 
 
3.4 Discussion 
We have shown, in a large population of ACS patients treated with contemporary 
therapies and followed up for up to one year, that fibrin clot properties independently 
predict the risk of spontaneous MI and CV death following initial in-hospital 
management. Importantly, lysis time predicted worse outcome after adjusting for other 
established or new prognostic biomarkers, thus indicating the potential for a further 
biomarker that provides insight into prognosis following ACS. The association between 
lysis time and the levels of the established biomarkers also raises the possibility that 
variability in fibrin clot properties might contribute to the association of these other 
biomarkers with thrombotic events. Given that antithrombotic therapy is mainly centred 
around antiplatelet agents following the acute phase, our data support the hypothesis that 
at least a subgroup of patients might benefit from additional therapy that aims at 
improving lysis potential. For example, further work could explore whether 
anticoagulant therapy, in combination with a platelet P2Y12 receptor antagonist, offers 
an advantage over dual antiplatelet therapy in those with adverse fibrin clot properties. 
Other novel therapies that specifically target proteins implicated in impaired lysis, such 
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as complement C3 or plasmin inhibitor, is another approach that might have less impact 
on haemostasis, particularly if the aim was to normalise lysis potential (249).  
Studying fibrin clot properties is attractive for many reasons. First, fibrinogen conversion 
and cross-linking of fibrin fibres to form a stable network is a key step in the formation 
of an obstructive vascular thrombus. Second, thrombotic occlusion of coronary arteries 
could represent a failure of the protective endogenous thrombolytic mechanisms to lyse 
clots before they become occlusive. Third, this assay provides a functional and simple 
assessment of the complex interactions between different clotting/lysis factors and other 
plasma proteins and takes into account both quantitative and qualitative changes in 
coagulation factors that may affect fibrinolytic efficiency (249, 250). Fourth, this is a 
relatively cheap, easy and reproducible test to perform and, importantly, fibrin clots that 
resist lysis might give us mechanistic insights into recurrent events.  
Previous studies, using different assays in whole blood, have shown a positive 
association between prolonged lysis and CV death (251, 252). Another study using 
thromboelastography in plasma showed similar results (253). However, these were small 
studies with limited event rates and assessment of clotting and lysis in whole blood 
cannot reliably differentiate between the cellular and protein components of thrombus 
formation.  
The relationships between adverse fibrin clot dynamics and some clinical characteristics 
demonstrated in our work are consistent with evidence obtained from smaller 
observational, cross-sectional studies. For example, DM, CKD and PAD, all high-risk 
conditions for cardiac ischaemia, have shown associations with adverse fibrin clot 
characteristics (143, 247, 248).  
Approximately a quarter of ACS patients have DM (7, 254). DM is associated with 
increased ischaemic and bleeding risk and this can make treating these patients 
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challenging (7, 78, 242, 255). Despite the strong association between DM and adverse 
fibrin clots, dense clots with resistance to lysis appear to offer additional prognostic 
information without an association with bleeding. Therefore, studying fibrin clots in 
patients with DM in particular, could be a useful tool to guide antithrombotic treatments 
in the future.  
Evidence suggests that inflammation results in prothrombotic states (138, 153). The 
strong correlations between fibrin clot properties and inflammatory markers support 
previous work demonstrating that inflammation leads to prothrombotic changes in fibrin 
clot dynamics and illustrates one mechanism for the higher risk of atherothrombotic 
events in patients with higher levels of inflammatory markers (195, 196).  
The relationship between maximum turbidity and worse outcomes lost significance after 
adjusting for other biomarkers. In contrast to lysis time, fibrinogen levels have greater 
effect on maximum turbidity (229, 256) and fibrinogen levels go hand-in-hand with 
inflammatory markers, particularly CRP (257). 
Interestingly, fibrin clot density and resistance to lysis increased with increasing levels 
of NT-proBNP and troponin T. The exact molecular mechanisms for these associations 
are difficult to ascertain. However, higher troponin T and NT-proBNP reflect larger 
infarcts and these are associated with a greater inflammatory response, which might 
account for some of the prothrombotic changes. NT-proBNP has been shown to add 
prognostic value regardless of the degree of necrosis after ACS (258). Our findings, 
therefore, point to an additional mechanism, beyond the increased risks of death from 
heart failure and arrhythmia associated with left ventricular systolic dysfunction, 
whereby NT-proBNP is associated with worse outcome, as a consequence of more dense 
fibrin clots that resist lysis leading to increased risk of atherothrombosis.   
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Turbidimetric analysis of fibrin clots requires trained laboratory personnel and therefore 
is not suitable as a bedside test. Similar to other clotting assays, results might be 
influenced by high-level anticoagulant therapy and significant liver conditions, which 
make results difficult to interpret in those scenarios. A limitation to this study is that it 
only provides a “snapshot” assessment of fibrin clot characteristics at hospital discharge 
(median 6 days). It is established that internal fibrinolytic activity has a circadian rhythm 
largely driven by variations in plasminogen activator inhibitor-1 activity (259). 
Unfortunately, sampling times are not available in our database but samples were 
collected during office working hours. The clear relationship with DM and biomarker 
levels, which were all measured at baseline, reassure us that variation is likely to be 
marginal. In Chapter 4, I seek to assess the stability of this phenotype over time and 
future analyses will explore how the relationship with clinical outcome could change in 
a stable patient cohort. 
3.5 Conclusions 
Despite strong relationships with clinical risk factors, particularly DM, and inflammatory 
and other prognostic biomarkers, the resistance of fibrin clots to lysis independently 
predicts CV death following ACS. These findings suggest that novel therapies targeting 
fibrin clot properties might be a new avenue for improving clinical outcomes in patients 
with ACS.  
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4 Prolonged Fibrin Clot Lysis Persists 1-month Following Acute 
Coronary Syndrome: A Plato Substudy  
4.1 Abstract  
Background: We have shown, in the previous chapter, that prolonged fibrin clot lysis at 
hospital discharge independently predicts cardiovascular death following ACS. The 
acute inflammatory response observed following ACS may drive some of the changes in 
fibrinolysis and therefore we studied fibrin clot properties 1-month post ACS and 
compared those to results obtained at hospital discharge.  
Methods: A validated turbidimetric assay was used to determine fibrin clot lysis time 
and clot maximum turbidity in 4,032 plasma samples collected at 1-month post-ACS 
from patients in the PLATO trial. Potential differences in clot properties at hospital 
discharge and 1 month were investigated. Change in clot parameters between discharge 
and 1 month was correlated to change in CRP and WCC levels.  
Results: There was little difference in mean (±SD) lysis time comparing hospital 
discharge with 1-month results (803±426 vs. 817±388 secs, respectively; P<0.001), the 
slight increase after hospital discharge being explained by in-hospital LMWH treatment. 
Conversely, mean maximum turbidity reduced from 0.51±0.19 AU at discharge to 
0.42±0.14 AU at 1 month (P<0.001). While the relationships between change in lysis 
time and change in inflammatory markers were weak, the relationship between change 
in clot maximum turbidity and change in CRP (in particular) appeared linear. The 
prevalence of diabetes mellitus, chronic kidney disease and peripheral artery disease was 
highest in the highest quartile groups of both lysis time (>882 secs) and maximum 
turbidity (>0.49 AU) at 1 month. 
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Conclusion: Resolution of systemic inflammation at 1-month post-ACS is associated 
with a drop in fibrin clot density but little effect on lysis potential. This indicates that clot 
density has little effect on lysis time and the derangement in fibrinolysis is not related to 
an enhanced inflammatory environment in ACS patients. The impact of contemporary 
therapy on lysis efficiency is limited, which may therefore constitute a suitable target for 
secondary prevention therapy, particularly in individuals with multiple risk factors.  
 
4.2 Background 
We have shown fibrin clots that resist lysis to be independently related to adverse clinical 
outcomes following ACS.  Prolonged lysis time and increased density were strongly 
related to acute inflammatory markers measured at baseline. In a human sepsis model, 
induced by endotoxin, acute inflammatory response resulted in prothrombotic changes 
in fibrin structure (153). Consequently, some of the adverse fibrin properties might be 
attenuated once inflammation settles.  
On the other hand, high-risk vascular conditions have shown a clear relationship with 
prolonged lysis and increased density indicating a possibly stable phenotype. Large 
longitudinal studies, exploring the change in fibrin clots following ACS, are lacking. 
Understanding the extent of change in this phenotype and how this relates to changes in 
inflammatory markers might aid our efforts to optimise treatment.  
In this chapter, I aim to study fibrin clot properties in plasma samples collected 1-month 
post ACS and compare measurements to results obtained at hospital discharge. 
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4.3 Results 
4.3.1 The relationships between fibrin clot properties, clinical characteristics and 
biomarkers 
Tables 4-1 and 4-2 summarise how different characteristics vary across the four quartile 
groups of lysis time and maximum turbidity.  
Similar to what was observed with hospital discharge results, higher percentages of 
patients in the highest quartile groups of both lysis time and maximum turbidity had DM, 
CKD and PAD. Body mass index also increased with increasing quartile groups of both 
lysis time and maximum turbidity.  
Interestingly, female patients had significantly longer lysis time. This observation was 
consistent with hospital discharge results.  
The associations between lysis time and baseline cystatin C, GDF-15 and CRP remained 
significant, with increasing values of each of these biomarkers in the highest quartile 
groups.  
Levels of baseline inflammatory markers and prognostic biomarkers (troponin T and NT-
proBNP) also significantly increased with increasing levels of maximum turbidity.  
1-month inflammatory markers were also significantly associated with both lysis time 
and maximum turbidity (Tables 4-3, 4-4).  
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Table 4-1: Baseline clinical characteristics and biomarkers across lysis time 
quartile groups 
Variables  Lysis time (secs) quartile group P value 
Q1 (<582) 
n = 1036 
Q2 (582-702) 
n = 1001 
Q3 (702-882) 
n = 989 
Q4 (>882) 
n = 1006 
Demographics and medical history 
Age (years)  62 (54 - 70)  62 (54 - 71)  62 (53 - 71)  61 (53 - 69) 0.33 
Female  198 (19.1%)  263 (26.3%)  324 (32.8%)  404 (40.2%)  < 0.001 
BMI (kg/m2) 27 (24.5 - 29.4)  27.7 (24.7 - 30.4)  27.7 (25.3 - 30.8) 28.7(25.7 - 31.7) < 0.001 
Current smoker  400 (38.6%)  379 (37.9%)  388 (39.2%)  331 (32.9%) 0.01 
Hypertension 583 (56.3%)  654 (65.3%)  659 (66.6%)  739 (73.5%)  < 0.001 
Hyperlipidaemia  407 (39.3%)  438 (43.8%)  404 (40.8%)  439 (43.6%)  0.11 
Diabetes mellitus 191 (18.4%)  204 (20.4%)  230 (23.3%)  277 (27.5%)  < 0.001 
PAD 50 (4.8%)  74 (7.4%)  54 (5.5%)  75 (7.5%)  0.03 
CKD  21 (2.0%)  30 (3.0%)  35 (3.5%)  45 (4.5%)  0.02 
Type of ACS 
STE-ACS  524 (50.6%)  481 (48.1%)  439 (44.4%)  443 (44.0%) 0.01 
Randomized treatment 
Ticagrelor  498 (48.1%)  485 (48.5%)  504 (51.0%)  510 (50.7%)  0.44 
Baseline biomarkers 
Troponin T (ng/L)  149 (42 - 564)  162 (39 - 542)  146 (39 - 567)  129 (30 - 455)  0.08 
NT-proBNP 
(pmol/L)  
357(122-1038)  396 (133-941)  410(131-1099)  369(126 - 1080)  0.78 
Cystatin C (mg/L)  0.8 (0.6 - 0.9)  0.8 (0.6 - 1.0)  0.8 (0.7 - 1.0) 0.9 (0.7 - 1.0) < 0.001 
GDF-15 (ng/L) 1446(1083-2044) 1505(1126-2136) 1570(1179-2154) 1536(1125-
2161) 
0.01 
CRP (mg/L)  2.7 (1.2 - 6.3)  2.7 (1.4 - 6.9)  4.0 (1.7 - 9.0)  4.4 (1.9 - 10.0) < 0.001 
WCC (*109/L) 9.2 (7.4 - 11.5)  9.3 (7.4 - 11.6)  9.4 (7.6 - 11.9)  9.5 (7.5 - 11.9)  0.27 
Values are medians (IQRs) for continuous data and n (%) for categorical data. BMI: body mass index; 
HTN: hypertension; DM: diabetes mellitus; MI: myocardial infarction; PAD: peripheral artery disease; 
CKD: chronic kidney disease; STE-ACS: ST-elevation acute coronary syndrome; NT-proBNP: N-terminal 
pro b-type natriuretic peptide; GDF: growth differentiating factor; CRP: C-reactive protein; WCC: white 
cell count. P values calculated using Chi-square test (categorical variables) or Kruskal-Wallis test 
(continuous variables) 
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Table 4-2: Baseline clinical characteristics and biomarkers across maximum 
turbidity quartile groups 
Variables Maximum turbidity (AU) quartile groups P value 
Q1 (<0.33) 
n = 1008 
Q2 (0.33-0.41) 
n = 1009 
Q3 (0.41-0.49) 
n = 1009 
Q4 (>0.49) 
n = 1006 
Demographics and medical history 
Age (years)  60 (53 - 69)  61 (53 - 70)  62 (54 - 71)  64 (56 - 71) < 0.001 
Female  276 (27.4%)  309 (30.6%)  295 (29.2%)  309 (30.7%)  0.32 
BMI (kg/m2) 27.1 (24.5 - 30)  27.5 (25.1 - 30.4)  28 (25.2 - 30.9)  28.1 (25.4 - 31.4)  < 0.001 
Current smoker  356 (35.3%)  371 (36.8%)  356 (35.3%)  415 (41.3%)  0.02 
Hypertension  617 (61.2%)  640 (63.4%)  672 (66.6%)  706 (70.2%)  < 0.001 
Hyperlipidaemia  434 (43.1%)  420 (41.6%)  428 (42.4%)  406 (40.4%)  0.64 
Diabetes mellitus  212 (21.0%)  191 (18.9%)  220 (21.8%)  279 (27.7%)  < 0.001 
PAD  43 (4.3%)  54 (5.4%)  63 (6.2%)  93 (9.2%) < 0.001 
CKD  23 (2.3%)  20 (2.0%)  32 (3.2%)  56 (5.6%) < 0.001 
Type of ACS 
STE-ACS  469 (46.5%)  468 (46.4%)  465 (46.1%)  485 (48.2%)  0.77 
Randomized treatment 
Ticagrelor  441 (43.8%)  471 (46.7%)  520 (51.5%)  565 (56.2%)  < 0.001 
Baseline Biomarkers 
Troponin T (ng/L)  135 (30.9 - 531)  136 (34 - 443.5)  153 (42 - 502)  179 (46.1 - 632.5) 0.01 
NT-proBNP 
(pmol/L)  
305 (106 - 793)  339 (109 - 900)  398 (140 - 1108)  525 (172 - 1466)  < 0.001 
Cystatin C (mg/L)  0.8 (0.6 - 0.9)  0.8 (0.6 - 0.9)  0.8 (0.7 - 1.0)  0.9 (0.7 - 1.1)  < 0.001 
GDF-15 (ng/L) 1403 (1039 -
2029)  
1400 (1072 -2004)  1539 (1126 - 
2091)  
1703 (1278 - 
2374)  
< 0.001 
CRP (mg/L)  2.5 (1.2 - 5.8)  2.6 (1.2 - 6.4)  3.4 (1.6 - 7.5)  5.3 (2.4 - 13.0)  < 0.001 
WBC (*109/L) 8.9 (7.1 - 11.3) 9.1 (7.3 - 11.4)  9.6 (7.5 - 11.6)  9.9 (8.1 - 12.1)  < 0.001 
Values are medians (IQRs) for continuous data and n (%) for categorical data. BMI: body mass index; 
HTN: hypertension; DM: diabetes mellitus; MI: myocardial infarction; PAD: peripheral artery disease; 
CKD: chronic kidney disease; STE-ACS: ST-elevation acute coronary syndrome; NT-proBNP: N-terminal 
pro b-type natriuretic peptide; GDF: growth differentiating factor; CRP: C-reactive protein; WCC: white 
cell count. P values calculated using Chi-square test (categorical variables) or Kruskal-Wallis test 
(continuous variables) 
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Table 4-3: 1-month biomarker levels across maximum turbidity quartile groups 
Variables Maximum turbidity (AU) quartile groups P value 
Q1 (<0.33) 
n = 1008 
Q2 (0.33-0.41) 
n = 1009 
Q3 (0.41-0.49) 
n = 1009 
Q4 (>0.49) 
n = 1006 
NT-
proBNP 
(pmol/L)  
400 (171 – 876)  406 (187 – 1021)  506 (207 – 1111)  709 (308 – 1551)  < 0.001 
CRP 
(mg/L)  
1.2 (0.7 – 2.4)  1.7 (1.0 – 3.1)  2.6 (1.4 – 4.7)  6.2 (3.1 – 12)  < 0.001 
WCC 
(*109/L) 
6.7 (5.7 – 7.7)  6.9 (5.9 – 8.1)  7.2 (6.2 – 8.4)  8.1 (6.8 – 9.4)  < 0.001 
Abbreviations as per tables 4-1 and 4-2. P values calculated using Kruskal-Wallis test.  
 
 
 
 
Table 4-4: 1-month biomarker levels across lysis time quartile groups 
Variables  Lysis time (secs) quartile group P value 
Q1 (<582) 
n = 1036 
Q2 (582-702) 
n = 1001 
Q3 (702-882) 
n = 989 
Q4 (>882) 
n = 1006 
NT-
proBNP 
(pmol/L)  
514(218– 1123)  470 (214 – 1098)  515 (205 – 1121)  501 (197 – 1107)  0.95 
CRP 
(mg/L)  
1.7 (0.8 – 3.7)  2.1 (1.1 – 4.4)  2.9 (1.4 - 6.0)  3.0 (1.4 - 6.2)  < 0.001 
WCC 
(*109/L) 
6.8 (5.7 – 8.2)  7.1 (5.8 – 8.4)  7.3 (6.2 – 8.6)  7.4 (6.3 – 8.8)  < 0.001 
Abbreviations as per tables 4-1 and 4-2. P values calculated using Kruskal-Wallis test.  
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4.3.2 Change in fibrin clot properties between hospital discharge and 1-month 
3,625 patients had fibrin clot measurements at both timepoints. Significant modest 
correlations were present between fibrin clot properties at hospital discharge and 1-
month post ACS (lysis time: r = 0.35, p < 0.001; maximum turbidity: r = 0.28, p < 0.001) 
(Figure 4-1).  
There was a slight increase in mean (±SD) lysis time at one month compared to hospital 
discharge (817±388 secs vs. 803±426 secs, respectively; P<0.001). This increase was 
more pronounced in patients who had received LMWH within two days of hospital 
discharge blood sampling (840±409 secs vs. 789±376 secs; P<0.001). In those who had 
not received LMWH within two days of hospital discharge sampling, there was no 
significant difference in lysis time (802±373 secs vs. 814±457 secs; P = 0.68).  
In contrast, mean (±SD) maximum turbidity dropped at one month compared to hospital 
discharge (0.42±0.14 AU vs. 0.51±0.19 AU, respectively; P<0.001). Amongst those who 
had received LMWH within two days of hospital discharge blood sampling, the change 
was similar (0.43±0.13 AU vs. 0.51±0.19 AU; P<0.001).  
To further characterise change in lysis time and maximum turbidity in paired samples, 
Bland-Altman plots were derived, excluding patients who had received LMWH within 
2 days of sampling (Figure 4-2). Mean difference in lysis time was 12 secs; however, 
there seemed to be a degree of variability in lysis time in a proportion of patients, 
particularly those with high lysis time measurements (Figure 4-2 A). Despite this, 70% 
of patients in the highest quartile group at hospital discharge, remained in the highest 
two quartile groups at 1-month. Variation in patients with DM appeared similar to the 
whole cohort (Figure 4-2).  
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Figure 4-1: Correlation between fibrin clot properties at hospital discharge and 1-
month (All patients) 
A: Scatter plot of lysis time (secs) at 1-month vs. hospital discharge. B: Scatter plot of maximum turbidity 
(AU) at 1-month vs. hospital discharge. r: Spearman correlation coefficient.  
 
 
 
Figure 4-2: Bland-Altman plots for change in lysis time (A) and change in maximum 
turbidity (B) 
n = 2160. This figure excludes patients who were on LMWH within two days of hospital discharge 
sampling. DM: diabetes mellitus.  
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4.3.3 The relationships between change in fibrin clot properties and change in 
inflammatory markers 
To measure change in inflammatory biomarkers, hospital discharge and 1-month CRP 
measurements were used. WCC was available at baseline and 1-month.  
Change in fibrin clot lysis time was only weakly related to changes in levels of 
inflammatory markers (Figure 4-3 A, B).  When excluding patients treated with LMWH 
within 2 days of blood sampling, similar very weak correlations were present between 
change in lysis time and change in inflammatory biomarkers (r ≤ 0.08).  
However, the relationship between change in fibrin clot turbidity and inflammatory 
markers was more pronounced and appeared linear with change in CRP levels (Figure 4-
3 C, D).  
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Figure 4-3: Relationship between change in inflammatory markers and change in 
fibrin clot parameters 
A: Scatter plot of change in lysis time vs. change in white cell count (WCC). B: Scatter plot of change in 
lysis time vs. change in C-reactive protein (CRP). C: Scatter plot of change in maximum turbidity vs. 
change in WCC. D: Scatter plot of change in maximum turbidity vs. change in CRP. r: Spearman 
correlation coefficient. Change is calculated based on log transformed values. 
4.3.4 The relationship between fibrin clot properties at 1-month and clinical 
outcomes  
During follow-up after the 1-month timepoint, 80 patients (1.9%) had CV death, 146 
(3.6%) had spontaneous MI and 192 (4.8%) had major bleeding.  
There was no significant relationship between lysis time and any of the clinical 
outcomes. However, the cumulative event rate of the combined outcome of CV death 
and spontaneous MI was higher in the highest quartile groups of lysis time driven by 
higher rates of CV death (Figure 4-4 A, B). 
After adjustment for randomised treatment, each 50% increase in maximum turbidity 
was associated with increased risk of CV death/spontaneous MI (HR 1.19; 95% CI 1.00-
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1.41; P = 0.046). As a categorical variable, the highest quartile group was associated with 
increased risk of CV death/spontaneous MI (HR 1.37; 95% CI 0.95-1.97; P = 0.017) and 
CV death alone (HR 1.88; 95% CI 1.09-3.26; P < 0.001) (Figure 4-4 C, D). This 
association, however, lost significance after adjustment for clinical risk factors (model 
1).    
 
Figure 4-4: Relationship between fibrin clot parameters and 1-year rates of CV 
death and spontaneous MI 
Kaplan-Meier curves for rates of:(A) the combined outcome of cardiovascular (CV) 
death/spontaneous myocardial infarction (MI) per quartile groups of lysis time, (B) CV 
death alone per quartile groups of lysis time, (C) combined outcome of CV 
death/spontaneous MI per quartile groups of maximum turbidity and (D) CV death alone 
per quartile groups of maximum turbidity.  
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4.4 Discussion 
For the first time, we have demonstrated, in a large longitudinal study, that fibrin clot 
lysis time remains relatively stable up to 1-month post ACS. This is despite the drop in 
fibrin clot density that appears to be driven by resolution of systemic inflammation. This 
indicates that fibrin clot density and inflammation have little impact on lysis potential. 
The relationship between high-risk conditions and increased density/prolonged lysis 
persisted at 1-month, giving us mechanistic insights into worse outcomes associated with 
those conditions.  
The relationship between female patients and prolonged lysis has also been demonstrated 
at both timepoints. This is consistent with previously observed results in other cohorts of 
high risk vascular patients (260, 261). Another study, in a younger cohort, found no 
difference in lysis potential between males and females (262). Prolonged lysis may be 
one mechanism for the loss of cardiovascular protection following menopause and 
further work is needed in this area to further understand mechanisms leading to this 
change.  
In a proportion of patients, lysis time appeared to change over time. It is difficult to 
elucidate factors driving this change. Different diets have been shown to have an impact 
on the degree of clotting factors activation and levels of fibrinolytic proteins (263, 264), 
and this maybe one reason for the change. Diurnal variations and different levels of 
exercise might be another reason (265). 
A limitation of this study is the lack of power to detect independent relationships between 
fibrin clot properties and clinical outcomes after 1 month post ACS. However, we have 
demonstrated these relationships for clinical outcomes following hospital discharge post 
ACS in chapter 3 and the trends for relationships with clinical outcomes after 1 month 
remained consistent with these. Notably, most events occurred early during the follow-
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up period and this may indicate the need for optimisation of therapy early following 
ACS. The relatively stable lysis phenotype supports the suitability of this being a 
therapeutic target.   
4.5 Conclusion 
Prolonged fibrin clot lysis persists at 1-month post ACS, despite a drop in fibrin clot 
density in line with resolution of systemic inflammation. Current secondary preventative 
therapy has little impact on fibrin clot lysis and, therefore, this may constitute a suitable 
therapeutic target.    
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5 The effects of factor Xa inhibitors on fibrin clot dynamics: A novel 
approach for assessing anticoagulant effect?  
 
5.1 Abstract 
Introduction: Increasing numbers of patients are treated with factor Xa inhibitors. 
Although routine monitoring is not required, establishing treatment effects might become 
essential in certain scenarios. Assays sensitive to low concentrations for factor Xa 
inhibitors are lacking. Adverse fibrin clots predicted outcomes following ACS and it is 
not clear how different factor Xa inhibitors might influence this prognostic biomarker. 
In this study, we aimed to assess the in-vitro effects of increasing concentrations of 
different factor Xa inhibitors on fibrin clot dynamics in plasma.  
Methods:  Fibrin clot lag time, maximum turbidity and lysis time were determined using 
a validated turbidimetric assay in plasma mixed with rivaroxaban, apixaban, 
fondaparinux and enoxaparin. Experiments were performed in plasma collected from 
healthy volunteers and ACS patients. Varying concentrations were studied.   
Results: All studied concentrations resulted in prolonged lag time with a clear dose-
response relationship. Significant effect on lag time was evident at the ultra-low 
concentrations of 10 µg/L rivaroxaban and apixaban (p < 0.01) and 330 µg/L 
fondaparinux (p < 0.01). Lysis potential was enhanced with concentrations expected to 
be achieved with high anticoagulation levels with fondaparinux, enoxaparin and 
rivaroxaban. Maximum turbidity was not clearly affected by the different anticoagulants.   
Conclusions: Fibrin clot lag time appears to be a sensitive assay for ultra-low 
concentrations of factor Xa inhibitors. High concentrations of factor Xa inhibitors 
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promote lysis potential. Fibrin clot lag time assay may be utilised in monitoring treatment 
but studies to confirm the observed effects ex-vivo are needed.   
5.2 Background 
 
The use of non-vitamin K antagonist oral anticoagulants (NOACs) is rapidly expanding. 
Current indications range from prophylaxis against thromboembolic disease in some 
orthopaedic patients, treatment of deep vein thrombosis and pulmonary embolism, stroke 
prevention in patients with non-valvular atrial fibrillation to secondary prevention in 
patients with ACS (266).  
Available NOACs include dabigatran, a thrombin inhibitor, and the directly-acting factor 
Xa inhibitors rivaroxaban, apixaban and edoxaban. Treatment indications are 
comparable, but low-dose rivaroxaban (2.5 mg twice daily) is the only NOAC to be 
successful in patients with CAD (9, 267). Advantages of these treatments include 
predictable pharmacokinetics, negating the need for routine monitoring or dose 
adjustments (266). They have also been largely shown to reduce the risk of intracranial 
haemorrhage compared to vitamin K antagonists (VKAs) (268). Consequently, NOACs 
are quickly replacing VKAs for the aforementioned indications.   
However, concerns regarding lack of reliable, sensitive and readily-available assays to 
monitor treatment effects of factor Xa inhibitors remain. 
In cases of extreme body weights, poor adherence to therapy, deteriorating renal or liver 
function, bleeding complications or urgent need for surgical intervention, it might 
become desirable to quantify treatment effects (269). Chromogenic determination of 
anti-Xa activity is currently the only recommended methodology. This, however, lacks 
sensitivity to low concentrations and anti-Xa levels do not necessarily correlate with 
bleeding risk (269). 
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Factor Xa inhibitors reduce thrombin generation, which might favourably modulate 
fibrin clot network. We have shown adverse fibrin clots that resist lysis to be a prognostic 
marker of worse outcomes following ACS and it is not clear how different anticoagulants 
might affect this prognostic marker. Fibrin clot dynamics might offer a novel approach 
to monitoring treatment effects. In these studies, we aimed to assess the in-vitro effects 
of different concentrations of different factor Xa inhibitors on fibrin clot formation and 
lysis in plasma samples.  
5.3 Results 
5.3.1 Effect of factor Xa inhibitors on fibrin clot formation 
Fibrin clot formation was studied in 6 healthy volunteers’ plasma samples with each of 
the anticoagulants (rivaroxaban, apixaban, fondaparinux), 6 ACS patients’ plasma 
samples with rivaroxaban, and 5 ACS patients’ plasma samples with apixaban and 
fondaparinux.  
In healthy volunteers’ control samples with DMSO, fibrin clot lag time measured 449 ± 
24 secs. This significantly increased to 529 ± 20 secs with 3.3 µg/L rivaroxaban (P = 
0.005) and significantly increased to 564 ± 23 secs with 10 µg/L apixaban (P = 0.001). 
In control samples without DMSO, fibrin clot lag time measured 495 ± 26 secs and 
significantly increased with 100 µg/L fondaparinux to 561 ± 25 secs (P = 0.012). 
Increasing concentrations of each of the anticoagulants resulted in further prolongation 
of fibrin clot lag time with a clear linear relationship (Figure 5-1).  
Similarly, fibrin clot lag time measured 432 ± 21 secs in control ACS samples with 
DMSO. This significantly increased to 602 ± 39 secs with 10 µg/L rivaroxaban (P = 
0.003) and 529 ± 23 secs with 10 µg/L apixaban (P = 0.002). In the absence of DMSO, 
fibrin clot lag time measured 445 ± 16 secs in control samples and increased to 618 ± 22 
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secs with 330 µg/L fondaparinux (P = 0.0005). Increasing concentrations of all 
anticoagulants also resulted in linear increase in fibrin clot lag time (Figure 5-1). 
There was no clear effect of any of the studied anticoagulants on fibrin clot turbidity 
(Figure 5-2).  
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Figure 5-1: The effects of rivaroxaban, apixaban and fondaparinux on fibrin clot 
lag time 
Y axis is log10 lag time (secs). Error bars represent mean ± SEM. * denotes a statistically 
significant result compared to control. Control samples diluted with same concentration 
permeation buffer and DMSO in rivaroxaban and apixaban experiments and diluted with 
permeation buffer only in fondaparinux experiments. All rivaroxaban/apixaban samples 
contained the same DMSO concentration (1/1000).  n = 6 in all experiments except for 
apixaban/fondaparinux experiments in ACS samples (n = 5).   
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Figure 5-2: The effects of rivaroxaban, apixaban and fondaparinux on fibrin clot 
maximum turbidity 
Error bars represent mean + SEM. AU: Arbitrary units. n = 6 in all experiments except 
for panels D,F (n = 5).  
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5.3.2 Effect of factor Xa inhibitors on fibrin clot formation and lysis  
Plasma samples from healthy volunteers were used to study anticoagulants’ effects on 
fibrin clotting and lysis. 16 samples were used with fondaparinux, 10 with enoxaparin 
and 6 with rivaroxaban.  
Similar to clotting-only assays, fibrin clot lag time prolonged with all studied 
anticoagulants (Figure 5-3 A). Sensitivity of the assay was, however, reduced and fibrin 
clot lag time started to significantly prolong with 100 µg/L rivaroxaban (P = 0.0004).  
Lysis potential was enhanced to varying degrees by all anticoagulants. In control samples 
with DMSO, lysis time measured 2403 ± 103 secs. This was significantly reduced with 
1000 µg/L rivaroxaban to 1175 ± 134 (P = 0.0001). A non-significant trend towards 
shorter lysis time started to appear with 100 µg/L rivaroxaban (Figure 5-3 B).  
In enoxaparin experiments, lysis time measured 2793 ± 168 secs in control samples. This 
was significantly reduced to 1200 ± 156 secs with 0.5 IU/ml enoxaparin (P < 0.0001) 
and remained low with 1 IU/ml enoxaparin (Figure 5-3 B).  
In fondaparinux experiments, lysis time measured 6664 ± 419 secs in control samples. 
This was significantly reduced to 5510 ± 350 secs with 500 µg/L fondaparinux (P = 
0.0005).  
At the studied concentrations, enoxaparin yielded greater antithrombotic effects than 
fondaparinux (Figure 5-3) and 4 samples did not clot with 1 IU/ml enoxaparin. 
Enoxaparin (0.5 IU/ml) resulted in 93 ± 10% increase in lag time. This is in contrast to 
41 ± 3% increase with fondaparinux (500 µg/L) (P < 0.0001). Similarly, enoxaparin (0.5 
IU/ml) resulted in 57 ± 5% reduction in lysis time, in contrast to 17 ± 3% reduction with 
fondaparinux (500 µg/L) (P < 0.0001).  
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Figure 5-3: The effects of enoxaparin, fondaparinux and rivaroxaban on fibrin clot 
lag time and lysis 
A: Anticoagulants’ effects on fibrin clot lag time. B: Anticoagulants’ effects on fibrin 
clot lysis time. Error bars represent mean + SEM. * denotes statistically significant result 
compared to control.  
5.4 Discussion 
We have shown in multiple experiments, using plasma samples from ACS patients and 
healthy volunteers, a linear relationship between drug concentration and fibrin clot lag 
time. This assay appears sensitive to ultra-low concentrations, which might be 
advantageous when it becomes necessary to monitor treatment effect. Furthermore, 
factor Xa inhibitors promoted lysis potential by reducing lysis time but this effect was 
only evident at high concentrations. We have shown lysis time to independently predict 
worse outcomes following ACS and promoting lysis might be one mechanism by which 
anticoagulants improve outcomes following ACS. However, targeting lysis inefficiency 
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with full anticoagulation long-term is unlikely to be tolerated in addition to dual 
antiplatelet therapy.  
Fibrin clot lag time is sensitive to concentrations expected with low-dose rivaroxaban 
(2.5 mg twice daily) (238).  
Clotting time, as measured by prothrombin time (PT), was previously shown to increase 
in response to rivaroxaban. However, this is hugely dependent on the reagent used and 
proved insensitive to low concentrations (270-272).  
Modifying PT by increasing calcium chloride concentrations and diluting thromboplastin 
yielded promising results (273). Increasing concentrations of apixaban gradually resulted 
in prolongation of the modified PT. This methodology also lacked sensitivity to low 
concentrations (<100 µg/L) (273).   
Fibrin clot lag time is relatively easy to perform and results are reproducible. Coefficient 
of variance (CV) in our experiments was consistently < 5%.  
Insights into optimal anticoagulation levels that are needed in different scenarios might 
be inferred by studying the effects of different anticoagulants on fibrin clots. For 
instance, subcutaneous fondaparinux (2.5 mg daily) has a similar efficacy to 
subcutaneous enoxaparin (1 mg/kg twice daily) in patients with NSTE-ACS but results 
in significantly lower major bleeding events (274). At clinically-relevant concentrations 
(275), enoxaparin had significantly greater effects on fibrin when compared to 
fondaparinux. These observations might explain the excess bleeding events observed 
with enoxaparin and imply that lower levels of anticoagulation are needed in this 
scenario. Enoxaparin also inhibits factor IIa (276) and this may explain the pronounced 
effects of enoxaparin on fibrin clots.  
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The observed effects on lysis time confirm results obtained in previous studies using 
different methodologies to study fibrin clot lysis (277, 278).  
Our studies have limitations as we have only assessed the in-vitro effects of these 
anticoagulants on fibrin clot.  We have, however, used a validated assay and our results 
mirror some of the ex-vivo effects previously observed with other anticoagulants (228, 
279).  
This assay is also performed on plasma, which limits its potential to be used as a bedside 
test. Similar to other clotting assays, results might be affected in coagulopathies such as 
those observed with significant liver disease.  
5.5 Conclusion 
Factor Xa inhibitors prolong fibrin clot lag time and improve lysis potential. Lag time 
assays appear sensitive to ultra-low concentrations, which might offer advantages over 
other available assays. Studies assessing the utility of fibrin clot lag time in monitoring 
therapy with factor Xa inhibitors are warranted.  
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6 Pharmacodynamic effects of a 6-hour regimen of enoxaparin in 
patients with ST-elevation myocardial infarction undergoing 
primary percutaneous coronary intervention (PENNY PCI study) 
Abstracts and publications arising from this chapter:  
1) The abstract has been presented at the Acute Cardiovascular Care Association 
conference in Milan 2018.  
2) Sumaya W, Parker WAE, Fretwell R, Hall IR, Barmby DS, Richardson JD, Iqbal 
J, Adam Z, Morgan KP, Gunn JP, Mason AE, Judge HM, Gale CP, Ajjan RA, 
Storey RF. Pharmacodynamic effects of a 6-hour regimen of enoxaparin in 
patients undergoing primary percutaneous coronary intervention (PENNY PCI 
study). Thrombosis and Haemostasis (in press).  
Including this data in my thesis does not violate copy rights agreements and is in 
agreement with other co-authors.  
6.1 Abstract 
Introduction: Delayed onset of action of oral P2Y12 inhibitors in ST-elevation 
myocardial infarction (STEMI) patients may increase the risk of acute stent thrombosis. 
Available parenteral antithrombotic strategies to deal with this issue are limited by added 
cost and increased risk of bleeding. We investigated the pharmacodynamic effects of a 
novel regimen of enoxaparin in patients undergoing primary percutaneous coronary 
intervention (PPCI).  
Methods: 20 STEMI patients were recruited to receive 0.75 mg/kg bolus of enoxaparin 
(pre-PPCI) followed by infusion of enoxaparin 0.75 mg/kg/6h. At 4 timepoints (pre-
anticoagulation, end of PPCI, 2-3 hours into infusion and at the end of infusion), anti-Xa 
levels were determined using chromogenic assays, fibrin clots were assessed by 
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turbidimetric analysis, and platelet P2Y12 inhibition was determined by VerifyNow 
P2Y12 assay. Clinical outcomes were determined 14 hours after enoxaparin initiation. 
Results: 19/20 patients completed the enoxaparin regimen; 1 patient, who developed no-
reflow phenomenon, was switched to tirofiban after the enoxaparin bolus. All received 
ticagrelor 180 mg. Anti-Xa levels were sustained during enoxaparin infusion (1.17 ± 0.06 
IU/ml at end of PPCI and 1.003 ± 0.06 IU/ml at 6 hr), resulting in prolonged fibrin clot 
lag time and increased lysis potential. Onset of platelet P2Y12 inhibition was delayed in 
opiate-treated patients. No patients had thrombotic or bleeding complications. 
 Conclusions: Enoxaparin 0.75 mg/kg bolus followed by 0.75mg/kg/6h provides 
sustained anti-Xa levels in PPCI patients. This may protect from acute stent thrombosis 
in opiate-treated PPCI patients who frequently have delayed onset of oral P2Y12 
inhibition.  
 
 
 106 
6.2 Background 
Dual oral antiplatelet therapy is essential in patients presenting with ST-elevation 
myocardial infarction (STEMI) and undergoing primary percutaneous coronary 
intervention (PPCI) (3).  
Potent P2Y12 inhibition, with prasugrel or ticagrelor, resulted in improved outcomes 
following acute coronary syndrome (ACS) (5, 6). Although these two agents provide 
rapid platelet inhibition in stable patients (72, 280), their onset of action can be delayed 
in patients undergoing PPCI, particularly those pre-treated with opiates, by up to 6-8 
hours (85-87, 281, 282).  This negative interaction might increase the risk of acute stent 
thrombosis (88), necessitating bridging therapy with parenteral antithrombotic treatment.  
Available parenteral therapies to deal with this issue include glycoprotein IIb/IIIa 
inhibitors (GPIs) or intravenous P2Y12 inhibition with cangrelor. These options have 
several limitations. GPIs increase the risk of major bleeding events and routine use has 
resulted in worse outcomes in several trials (90, 283-285). Cangrelor has some 
advantages: It inhibits platelet P2Y12 receptors within two minutes and has rapid offset 
of action over 1 hour after cessation of infusion (286). However, it has primarily been 
used as a 2-hour infusion and this might not be sufficient in patients with more than 2 
hours delay in onset of oral P2Y12 inhibition. Moreover, the very rapid offset of action 
may pose a risk should the infusion be interrupted. GPIs and cangrelor are costly, another 
factor that is likely to limit widespread routine use.  
Enoxaparin, a low-molecular-weight heparin, targets factor Xa and, to a lesser extent, 
factor IIa (thrombin) (276). It has a relatively short half-life (1.5 – 2 hrs when given 
intravenously) (287) and provides more predictable antithrombotic effect compared to 
unfractionated heparin, negating the need for monitoring (288). A bolus dose of 0.5 – 
0.75 mg/kg of enoxaparin can be given to support the PPCI procedure (289).  
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We have noted cases of acute stent thrombosis to occur at times when the effects of 
procedural anticoagulant are expected to be dissipating (290).  
We hypothesized that an infusion of enoxaparin (0.75 mg/kg/6h) following a bolus dose 
of 0.75 mg/kg would provide sufficient and sustained antithrombotic effects to bridge 
treatment with oral P2Y12 inhibition in STEMI patients undergoing PPCI, without the 
need for GPIs or cangrelor. In this study, we aimed to study the pharmacodynamic effects 
of this regimen.  
6.3 Results 
6.3.1 Baseline characteristics 
20 patients were recruited; 19 patients completed the full enoxaparin regimen and 1 
patient was switched to tirofiban due to no-reflow phenomenon prior to starting 
enoxaparin infusion. No patient had eGFR < 30 mls/min. Median age was 67 years, 80% 
were males, 45% had anterior STEMI, all had PPCI through the radial artery approach 
and 1 patient required an intra-aortic balloon pump. All patients received a loading dose 
of 180 mg ticagrelor pre-PPCI. Other baseline and procedural characteristics are 
summarised in table 6-1.  
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Table 6-1: Baseline and procedural characteristics 
Variable Value 
Age (years – median [IQR]) 67 (57-77) 
Male sex (%) 16/20 (80%) 
Caucasian race (%) 18/20 (90%) 
Anterior STEMI (%) 9/20 (45%) 
Smoking (%) 12/20 (60%) 
Hypertension (%) 9/20 (45%) 
Diabetes mellitus (%) 3/20 (15%) 
Chronic kidney disease (%) 3/20 (15%) 
Previous acute coronary syndrome (%) 3/20 (15%) 
Previous PCI (%) 2/20 (10%) 
Pain to balloon time (mins – median [IQR]) 205 (131-364) 
Call to balloon time (mins – median [IQR]) 146 (114-179) 
Door to balloon time (mins – median [IQR]) 47 (41-65) 
Stent length (mm – median [IQR]) 22 (14-30) 
Stent diameter (mm – median [IQR]) 3.5 (3-4) 
Ticagrelor loading to 1st blood sampling (mins – median [IQR]) 20 (10-40) 
Ticagrelor loading to 2nd blood sampling (mins – median [IQR]) 60 (50-95) 
Ticagrelor loading to 3rd blood sampling (mins – median [IQR]) 185 (175-220) 
Ticagrelor loading to 4th blood sampling (mins – median [IQR])  405 (390-425) 
STEMI: ST-elevation myocardial infarction; PCI: percutaneous coronary intervention. Chronic kidney 
disease is defined as estimated glomerular filtration rate (eGFR) < 60 ml/min.  
6.3.2 Pharmacodynamic assessments 
Anti-Xa levels peaked at the end of PPCI (1.17 ± 0.06 IU/ml) and were subsequently 
sustained both 2-3 hours into infusion (1.01 ± 0.05 IU/ml) and at the end of infusion 
(1.003 ± 0.06 IU/ml) (Figure 6-1). 
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Figure 6-1: Anti-Xa levels 
A scatter plot demonstrating anti-Xa levels throughout the studied time-points (n = 19). 
Variance during the infusion was assessed using one-way analysis of variance 
(ANOVA). Error bars represent standard error of the mean.  
 
Pre-anticoagulation, fibrin clot formation was rapid with a lag time of 165 ± 4.4 secs. 
This significantly prolonged at the end of PPCI (431 ± 29 secs; P = 0.0001 vs baseline) 
and remained prolonged during the infusion at 2-3 hours (395 ± 13 secs; P = 0.0001) and 
at the end of infusion (337 ± 6.6 secs; P = 0.0001) (Figure 6-2 A).  
Fibrin clot maximum turbidity measured 0.45 ± 0.02 AU pre-anticoagulation. This 
significantly dropped at the end of PPCI (0.24 ± 0.02 AU; P = 0.0001 vs baseline) and 
gradually increased during the infusion (0.36 ± 0.03 AU; P = 0.0012 vs baseline) 
returning to baseline at the end of infusion (0.43 ± 0.02 AU; P = 0.7 vs baseline) (Figure 
6-2 B). 
 110 
Pre-anticoagulation, lysis time measured 3161 ± 339 secs. This significantly dropped by 
the end of PPCI (2192 ± 489 secs; P = 0.001 vs baseline) and remained low during the 
infusion (2128 ± 256 secs; P = 0.014 vs baseline) and at the end of infusion (2124 ± 259 
secs; P = 0.009 vs baseline) (Figure 6-2 C).  
There is a degree of variability in antithrombotic effects. Dosing was based on weight 
estimation. This is likely to account for the outlying measurements in figures 6-1/6-2.  
 
 
 
 
Figure 6-2: The effects of enoxaparin on fibrin clot properties  
Scatter plots demonstrating fibrin clot properties pre- and throughout treatment with 
enoxaparin. PPCI: primary percutaneous coronary intervention; AU: arbitrary units. 
Error bars represent standard error of the mean. *** denotes P < 0.001, ** denotes P < 
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0.01, * denotes P = 0.01, ns: non-significant (P = 0.7); all compared to baseline (T1) and 
calculated using Dunnett’s multiple comparisons tests.  
 
A subset of 11 patients had thromboelastometry measured at all four time-points. Only 
clotting time was significantly prolonged throughout the infusion (Figure 6-3).  
 
 
Figure 6-3: The effects of enoxaparin on thromboelastometry 
Scatter plots of all thromboelastometry measurements (n = 11). T1: pre-anticoagulation; 
T2: end of primary angioplasty; T3: 2-3 hours into infusion; T4: end of infusion. * 
denotes significant difference compared to baseline (T1) (P < 0.001) calculated using 
Dunnett’s multiple comparisons tests. 
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6.3.3 P2Y12 inhibition  
All patients were P2Y12 inhibitor naive on presentation. Time from ticagrelor loading to 
different timepoints is summarised in table 6-1.  
One patient who did not receive opiates had evidence of P2Y12 inhibition at the beginning 
of PPCI (100 mins post loading with ticagrelor). The other opiate-free patient had > 20% 
P2Y12 inhibition by the end of PPCI whereas the remaining 17 patients, who had received 
morphine, had 0% inhibition at this timepoint (Figure 6-4). Poor P2Y12 inhibition 
remained common in morphine-treated patients throughout the 6-hour infusion with 8/19 
patients still having 0% inhibition at 6 hours despite treatment with anti-emetics 
(metoclopramide ± ondansetron) in all but 3 of these patients. Treatment with anti-
emetics did not affect P2Y12 inhibition (interaction P = 0.26) (Figure 6-5). Only 1 patient 
vomited following ticagrelor’s administration and was subsequently re-loaded with 
ticagrelor shortly after PPCI.  
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Figure 6-4: Platelet P2Y12 inhibition throughout the infusion (VerifyNow P2Y12 
assay) 
A: Bar graph highlighting the percentage of patients with 0% inhibition as determined 
by VerifyNow. Two patients did not receive opiates and had > 20% inhibition by end of 
PCI (as indicated by arrow). B: Scatter plot demonstrating the corresponding P2Y12 
reaction units throughout the studied time-points.  
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Figure 6-5: P2Y12 reactivity units in opiate-treated patients according to co-
administration of anti-emetics 
VerifyNow P2Y12 results in opiate-treated patients (n = 17) according to co-
administration of anti-emetics.  
6.3.4 Clinical outcomes 
None of the patients suffered any thrombotic or bleeding complication during the follow-
up period.  
6.4 Discussion 
We have studied the pharmacodynamic profile of a novel enoxaparin regimen in STEMI 
patients undergoing PPCI and have shown that it results in sustained anti-Xa levels 
throughout the 6-hour infusion. This regimen positively modulated fibrin clot properties, 
prolonging lag time, reducing fibrin clot density and improving lysis potential, indicating 
the formation of less thrombotic clots (32, 143). We have identified inefficient lysis as 
an independent predictor of cardiovascular death following ACS and so this regimen 
might help to improve prognosis.  
The universal prolongation of lag time following enoxaparin was prominent and 
consistent throughout, which may provide a useful functional measure of response to this 
therapy. Interestingly, fibrin clot studies provided more consistent data compared with 
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thromboelastometry, suggesting a higher sensitivity of this method at detecting the anti-
thrombotic effects of enoxaparin.  Despite high prevalence of delayed response to 
ticagrelor, none of our patients suffered acute stent thrombosis, providing preliminary 
support for the hypothesis that this regimen may be sufficient to bridge therapy with oral 
P2Y12 inhibitors in opiate-treated STEMI patients.  
Delayed absorption of oral P2Y12 inhibitors in STEMI patients is increasingly recognised 
by interventional cardiologists as a stent thrombosis risk. Crushing tablets has been 
attempted as a way to accelerate absorption of oral P2Y12 inhibitors (291-293). However, 
results were marginal and delayed absorption in a proportion of patients remains a risk. 
Our results also confirm that delayed P2Y12 inhibition is not attenuated by concomitant 
treatment with antiemetic therapy.  Therefore, parenteral therapies are likely to be needed 
in order to protect a large majority of patients. 
This novel enoxaparin regimen has the advantage of being simple and easy to implement 
in an emergency situation. Enoxaparin is also widely used for many other indications 
with good tolerability. Moreover, it is inexpensive and therefore likely to offer 
substantial savings when compared to GPIs or cangrelor.  
We should acknowledge the limitations of our study. This is a pharmacodynamic study 
and clinical outcomes are only reported as pilot outcomes. Larger studies are needed to 
establish the safety and efficacy of the studied enoxaparin regimen in STEMI patients 
undergoing PPCI. Furthermore, platelet P2Y12 inhibition was only studied with one 
methodology, although we have found this methodology to be most discriminatory in 
assessment of platelet P2Y12 inhibition (92). A high percentage of patients had poor 
platelet inhibition by the end of infusion, which raises the possibility that the duration of 
infusion might not be sufficient. However, enoxaparin’s half-life is ~2 hours and more 
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P2Y12 inhibition is highly likely to be established by 8 hours after loading dose of 
ticagrelor. This requires further assessment in future work.  
6.5 Conclusion 
A bolus dose of enoxaparin (0.75 mg/kg) followed by an infusion of 0.75 mg/kg/6h 
results in sustained pharmacodynamic effects throughout the infusion in STEMI patients 
undergoing PPCI. The efficacy and safety of this regimen in bridging therapy with oral 
P2Y12 inhibitors should be evaluated in larger studies.  
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7 Discussions and Future Directions 
7.1 Summary and significance of findings 
As a clinician, I have often seen patients coming back with recurrent symptoms, 
myocardial infarctions or even dying following ACS. This is despite our best efforts 
including revascularisations and offering contemporary antithrombotic therapy. This 
drove my ambition to pursue research to understand some mechanisms behind worse 
outcomes and explore possible options to optimise treatment.  
For the first time, in a large longitudinal study, I was able to show inefficient fibrin clot 
lysis to be a prognostic biomarker despite adjustment for multiple novel and established 
risk predictors. Although association does not conclude causation, this novel biomarker 
also showed clear associations with established high-risk disease states such as diabetes 
mellitus, chronic kidney disease, peripheral artery disease and inflammation, which may 
give us mechanistic insights into worse clinical outcomes following ACS.  
Furthermore, we have also shown that fibrin clot density (measured by turbidity) only 
modestly relates to lysis tendency. Turbidity might be more a reflection of fibrinogen 
levels, which might explain the linear relationship between change in turbidity and 
change in inflammatory markers. This is in contrast to lysis potential, which showed a 
higher degree of stability following ACS despite resolution of inflammation.  
High-risk conditions are associated with increased thrombotic potential through a variety 
of mechanisms. All these conditions have been associated with endothelial dysfunction, 
inflammation, hyperlipidaemia and increased platelet turnover. This leads to increased 
platelet reactivity, which is successfully targeted by dual antiplatelet therapy. However, 
increased levels of different coagulation factors and antifibrinolytic proteins 
(plasminogen activation inhibitor-1, thrombin-activatable fibrinolysis inhibitor, 
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complement C3, a2  plasmin inhibitor) leads to lysis inefficiency and this remains 
unaffected with current therapy, thus potentially constituting a therapeutic target (Figure 
7-1).  
  
Figure 7-1: Mechanisms for increased thrombotic risk 
PAI-1: plasminogen activation inhibitor-1; TAFI: thrombin-activatable fibrinolysis 
inhibitor. LDL-C: low-density lipoprotein cholesterol. This figure was included in a 
previous publication (Sumaya W et al. Fibrin clot properties independently predict 
adverse clinical outcome following acute coronary syndrome: A PLATO Substudy. 
European Heart Journal 2018;39:1078-85). Including this figure does not violate 
copyright agreements.  
 
Anticoagulation might be one approach to modulate lysis tendency. However, the in-
vitro studies suggest that this is only possible at high concentrations. Anticoagulation, in 
addition to the current approach of dual antiplatelet therapy, is likely to be risky, leading 
to unacceptable bleeding risk. However, it may be a viable option in addition to a single 
antiplatelet agent.  
We have also seen fibrin clot lag time to be affected by treatment with low-molecular-
weight heparins. This was confirmed by in-vitro studies and lag time appeared sensitive 
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to ultra-low concentrations of factor Xa inhibitors. Other assays lack sensitivity to low 
anticoagulant levels and therefore this assay may be advantageous. If confirmed in future 
ex-vivo studies, this has the potential of improving treatments in cases where 
pharmacokinetics can be unpredictable, such as in those with chronic kidney disease.  
One of the caveats of current antithrombotic therapy is the delayed absorption of oral 
P2Y12 inhibitors in STEMI patients and this may increase stent thrombosis risk. A novel 
regimen of enoxaparin infusion following a bolus dose provided consistent anti-Xa levels 
and consistently promoted lysis potential over 6 hours. Therefore, this may improve 
prognosis. Despite a high prevalence of delayed P2Y12 inhibition, there were no 
thrombotic complications providing preliminary pilot data in support of this regimen.  
There is no consensus on how to best deal with the delayed P2Y12 inhibition but current 
treatment options are costly and can increase bleeding risk. If this intervention is 
successful in future trials, it has the potential of improving patient outcomes and offering 
substantial savings to healthcare systems around the world. The cost of enoxaparin is 
~£14 per patient compared to ~£184 for glycoprotein IIb/IIIa inhibitors and ~£500 for 
cangrelor. In the UK, over 25,000 patients per year are treated with primary angioplasty 
(294). Approximately 80% of those receive opiates and therefore this approach could 
offer the NHS a saving of at least £3.4 million/year.  
7.2 Future research 
7.2.1 Lysis potential as a therapeutic target  
a) Anticoagulation: Although high levels of anticoagulation are likely to be needed 
to promote lysis, this may be possible in a selected cohort of patients who 
consistently demonstrate lysis inefficacy. For instance, patients with diabetes 
mellitus may benefit from anticoagulation in addition to a P2Y12 inhibitor as a 
secondary prevention strategy (295).  
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b) Inhibiting factor XIII: As discussed in chapter 1, factor XIII plays a critical role 
in incorporating antifibrinolytic proteins in the fibrin mesh and in the stability of 
thrombi by cross linking fibrin fibres. Inhibiting factor XIII may be a risky 
strategy since rare cases of factor XIII deficiency have resulted in significant 
bleeding (296). Moreover, mice deficient of factor XIII were at risk of myocardial 
rupture following myocardial infarction (297).  However, careful inhibition may 
be successful and in-vitro studies inhibiting factor XIII with a transglutaminase 
inhibitor have promoted lysis (149).  
c) Targeting one of the antifibrinolytic proteins: This is certainly an exciting avenue 
to explore. I have discussed that TAFI breaks the positive feedback loop between 
fibrin and plasmin by cleaving C-terminal lysine residues. Mice deficient in TAFI 
have normal development with no tendency towards increased bleeding (298). A 
novel compound, DS-1040, that targets activated TAFI has been developed. A 
pilot study in healthy volunteers showed improved lysis tendency without any 
significant adverse events (299). These studies provide reassuring data regarding 
the safety of such a treatment strategy.  Further trials are currently ongoing in 
patients presenting with acute stroke (clinicaltrials.gov: NCT03198715, 
NCT02586233).  
We have also discussed the key role of PAI-1 in inhibiting fibrinolysis. 
Atherosclerotic mice deficient in PAI-1 had attenuated progression of 
atherosclerotic plaques and less tendency to develop occlusive thrombi following 
vascular injury (300). These interesting findings support the hypothesis of 
recurrent mural thrombi to be implicated in atherosclerosis progression and imply 
a pathogenic role for PAI-1 in this.  
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Therapeutic options to target PAI-1 have been developed (301) and inhibiting 
PAI-1 did not result in prolonged bleeding time in primates (302) and had 
favourable antithrombotic effects (303).  
α2-PI is another potential therapeutic target. Mice deficient in α2-PI had smaller 
infarct size following ligation of their cerebral arteries (304). Similarly, inhibiting 
α2-PI resulted in smaller infarct sizes (305).  
In a pulmonary embolism animal model, targeting α2-PI with an antibody had 
similar efficacy to thrombolysis with no effect on bleeding (306).  
d) Identification of new molecules: It may be possible to perform genetic studies to 
link certain genes to the prolonged lysis phenotype. This may be successful at 
identifying a new pathway and a novel therapeutic approach.  
e) Anti-inflammatory treatment: CANTOS was recently successful at reducing 
recurrent events in ACS patients with raised inflammatory markers. We have 
shown clear associations between inflammation and adverse fibrin clots. 
Therefore, attenuating fibrin clot dynamics might be one mechanism for 
improved outcomes with anti-inflammatory therapy. Exploring the effects of 
such therapy on fibrin clots could help us understand the relationship between 
thrombosis and inflammation and may aid selecting treatment in the future.  
7.2.2 Using lysis time as a biomarker 
Multiple biomarkers have been studied in the past and many failed to add additional 
prognostic value beyond the known clinical risk predictors (307). The only biomarker to 
be routinely measured is troponin. Troponin adds great value as a diagnostic and 
prognostic test and therefore guides therapy.  
An ideal biomarker should be able to discriminate between low-, moderate- and high- 
risk patients regardless of their other clinical risk predictors. This is certainly challenging 
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to identify. Recently, GDF-15 emerged as a promising biomarker but the added benefit 
beyond the known clinical risk factors is small (202).  
Overall, lysis time only modestly added to the accuracy of a clinical risk prediction 
model. However, this is a functional thrombotic assay and may be utilised in aiding 
clinicians to decide which coagulation arm to target (cellular component vs. protein arm). 
For instance, guided dual antithrombotic therapy with a P2Y12 inhibitor and an 
anticoagulant (based on lysis time) could be compared to the usual approach of dual 
antiplatelet therapy following ACS.  
7.2.3 Fibrin clot lag time as a novel approach to monitor anti-Xa effects 
Clinical studies to confirm the ex-vivo effect of factor Xa inhibitors on fibrin clot lag 
time and compare this effect to chromogenic determination of anti-Xa levels are needed.  
7.2.4 Enoxaparin infusion as a novel antithrombotic regimen in primary PCI 
We have secured further funding to complete a second-stage feasibility study, which will 
hopefully aid our bid to obtain further funding for a well-powered RCT.   
 
Overall, I believe my work towards a PhD has advanced our knowledge and 
understanding of risk following ACS. In particular, it uncovered the potential need to 
target both the protein and cellular phase of coagulation in order to optimise anti-
thrombotic therapy following acute myocardial infarction. Also, my data suggest that 
higher risk patients, such as those with diabetes or chronic renal disease, require a more 
aggressive anti-thrombotic strategy. Importantly, my data indicate that anti-thrombotic 
therapy should perhaps be individualised in the future and the current approach, with few 
exceptions, of “one size fits all” requires refinement.  
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Many avenues could be explored in order to optimise treatments and improve prognosis 
following ACS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 Appendix 
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8.1 PLATO bleeding definitions 
• Major life-threatening: Fatal, intracranial, intrapericardial with cardiac 
tamponade, hypovolaemic shock or severe hypotension due to bleeding and 
requiring pressors or surgery, a decline in the haemoglobin level of 5 g/dL or 
more, requiring transfusion of at least 4 units of red cells (5).  
• Other major bleeding: Leading to clinically significant disability (eg. 
Intraocular bleeding with permanent vision loss), associated with a drop in 
haemoglobin of at least 3 g/dL and less than 5 g/dL, requiring transfusion of 2-3 
units of red cells (5).  
• Minor bleeding: Any bleeding requiring medical intervention but not meeting 
the above-mentioned criteria (5).   
8.2 Fibrin clot data distribution in PLATO 
 
Distribution of fibrin clot properties data was not normally distributed (Figure 8-1 A, C). 
We have therefore natural-log transformed our data to give a better mirror of the normal 
distribution and enable us to estimate Cox proportional hazards ratios (Figure 8-2 B, D).  
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Figure 8-1: Distribution of fibrin clot properties 
 
8.3 The effects of citrate concentrations on fibrin clot measurements 
Citrated plasma was used in all our experiments. In all fibrin experiments, I have used a 
standardised calcium chloride concentration. Underfilling citrated blood tubes might 
result in increased concentrations of citrate and consequently might affect fibrin clot 
measurements. Haematocrit did not seem to influence fibrin clot measurements which 
reassures us that any effect is likely to be marginal. Furthermore, I have performed in-
vitro experiments by mixing plasma samples collected from healthy volunteers with 
additional 3.2% citrate (1:10). Additional citrate did not result in any significant change 
in fibrin clot parameters (Figure 8-2).  
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Figure 8-2: Effects of additional citrate on fibrin clot properties 
A: Effect of additional citrate on maximum turbidity; B: Effect of additional citrate on 
lysis time. N = 5. P values calculated by using paired t tests.   
 
8.4 Studying fibrin clot properties with tissue factor 
To study the effects of factor Xa inhibitors on fibrin clot formation and lysis, thrombus 
formation should be induced upstream of thrombin. For this, I have used tissue factor. 
To optimise the assay, I have studied multiple concentrations of tissue factor (0.001 pM, 
0.005 pM, 0.01 pM, 0.1 pM, 1 pM and 5 pM). Tissue factor did not have any additional 
effect beyond re-calcification at concentrations < 0.1 pM. Moreover, below 1 pM, the 
reproducibility of the assay was compromised (coefficient of variance > 20%). The 
effects of different concentrations are shown in figure 8-3. To select a sensitive assay, I 
chose 1 pM as the lowest concentration that gave reproducible results. 
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Figure 8-3: Fibrin clot assay with different concentration of tissue factor  
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PENNY PCI Case Report Form 
Screening 
 
Details of presentation 
 
Date of onset of symptoms                                            
 /  / 
 
Time of onset of symptoms 
 
 
 
Eligibility criteria 
 
Age ≥ 18 years                                                           Yes                No       
Confirmed STEMI diagnosis On the basis of ECG      Yes               No 
and history                                                          
 
 
Pre-treatment with ticagrelor or prasugrel                   Yes                No           
                            
 
Intention to proceed with PPCI             Yes              No 
 
Feasibility to obtain verbal consent                              Yes                No 
  
Exclusion criteria: 
Active bleeding that cannot be controlled by       Yes  No 
local measures  
       
Pregnant patients                                                  Yes       No 
      
          
Patients with end stage renal failure    Yes  No 
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requiring renal replacement therapy      
   
Known thrombocytopenia (Platelet count < 100,000/L) Yes       No 
        
Known history of intracranial haemorrhage   Yes  No 
    
Known current treatment with oral anticoagulants  Yes  No 
 
Known history of major surgery or trauma or  
history of GI/GU haemorrhage within the last month  Yes  No 
    
 
Known intracranial malignancy or aneursym  Yes  No 
   
Known allergy to enoxaparin    Yes            No 
 
Known hypersensitivity to benzylalcohol                      Yes               No 
Patients with acute bacterial endocarditis                    Yes               No 
Active gastric or duodenal ulceration                           Yes               No 
  
Inability to easily understand verbal information given  
in English for any reason                                                Yes         No 
 
Inability to give informed consent due to either temporary 
 or permanent mental incapacity                                            Yes No 
 
Current participation, or participation within the last month     Yes        No 
 in an interventional clinical trial. 
 
Verbal informed consent obtained for study (prior to procedure) on  
 
 /  / at       :    
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Brief PIS supplied to patient: Version                     
 
Date               /               / 
 
 
 
Signature 
 
 
 
 
Coronary angiogram confirming diagnosis of STEMI    
        Yes                    No 
 
Person taking verbal consent and confirming 
eligibility 
 
 
Signature  
 
Patient enrolled at       : 
 
Date of birth 
 /  / 
 
Age   
Years  Months 
 
Note. If <18 years old do not proceed 
 
Male   Female  
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Race/Ethnicity      Caucasian          Black           Asian           other  
 
 
Height    cm 
 
 
Weight    Kg 
 
 
Smoking Status  Current  Past                  Never 
 
PMH  
      Yes   No 
 
Hypertension     
 
Dyslipidaemia  
 
Heart Failure 
 
Asthma 
 
COPD 
 
Other Lung disease 
 
Peripheral arterial disease 
  
Type II DM 
 
Type I DM 
 
CKD (eGFR <60ml/min) 
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Acute or chronic liver disease 
 
ACS (excluding current episode)  
 
Stable angina 
 
Prior PCI (excluding current episode)  
 
Prior CABG (excluding current episode)  
 
TIA 
 
Non Haemorrhagic stroke  
 
 
Epistaxis in the last 12 months  
 
Other non trivial bleeding in the last 12 months 
 
 
 
Other Medical/Surgical history 
 
 
 
 
 
 
 
 Aspirin administered in ambulance   Yes      No     
 
   
 Dose of Aspirin                  mg              Time              :    
 
 
             
mgmg 
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Ticagrelor administered            Yes        No    
    
 
Dose of ticagrelor                    mg              Time              :    
 
 
 
Prasugrel administered           Yes        No    
 
       
 
Dose of prasugrel                    mg             Time           :  
 
 
 
 
Opiate treatment                   Yes                                               No 
 
If yes:  
 
Drug and dose :                                     mg        Time                     : 
 
 
Other concomitant medications to be recorded on page 10.  
 
Physical examination 
 
 
Vital Signs  
 
BP                        /                mmHg 
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HR    beats per minute 
 
 
Body temperature          .   ˚C 
 
 
ECG 
 
ECG Interpretation 
 
 
 
 
 
 
 
 
 
 T1 bloods 
 
Blood sample prior to anticoagulation 
 
Taken on                      /               / 
   
Taken at                  :               (at start of PPCI) 
 
 
 
Enoxaparin dose (0.75 mg/kg)                   mg   
 
 
Person preparing the bolus dose     
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Bolus of IA/IV enoxaparin given (0.75 mg/kg) (pre PCI)  
 
Date    /    / 
 
Time                    : 
 
 
PPCI started  Time     : 
 
 
IV enoxaparin infusion (0.75mg/kg) started: (0.75 mg/kg added to 250 mls 
of saline and set to be given at a rate of 42 mls/hour) 
 
Date    /    / 
 
 
Time                    : 
 
 
 
Person preparing enoxaparin:  
 
 
 
 
Person prescribing enoxaparin  
(Bolus + infusion)   
 
 
Date and time of remaining                           /                / 
enoxaparin disposal (both vials) 
                                                                            : 
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Person confirming disposal of enoxaparin vials:  
 
 
 
 
 
 
T2 bloods 
 
 
PPCI Finished at                 : 
 
 
Blood sample (at end of PPCI) 
 
Taken on                      /               / 
   
Taken at                  :                
 
 
 
Written informed consent obtained on 
 
 /  / at       :    
 
 
GP letter sent  
 
Blood test results 
Kidney function 
Na                                      K  
 
 
Urea                                  Creatinine                                 
    
        
            
   
 
                 
mmol/L 
                 
mmol/L 
                
mmol/L 
                 
µmol/L 
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 eGFR 
 
Full blood count 
Hb                                     WCC                                     
 
 
  Platelets                                 RCC 
 
   MCV                                       MCH 
 
 
Clotting profile 
PT                                     APTT                                  
 
 
Fibrinogen  
 
 
 
T3 bloods 
 
 
Blood sample (2-3 hours from start of enoxaparin infusion) 
 
 
Taken on                      /               / 
   
Taken at                  :                
 
 
If eGFR < 30 ml/min: 
 
 
    
        
                         
ml/min 
                        
g/L 
               
X109/L 
                  
X109/L 
              
X1012/L 
fl 
                     
Pg 
              secs                    
secs 
                    
g/L 
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IV enoxaparin infusion stopped (at 3 hours): 
 
Yes    No  
 
Date Stopped  /    / 
 
 
Time Stopped                : : 
 
 
T4 bloods 
 
 
IV enoxaparin infusion finished (after 6 hours): 
 
Date    /    / 
 
 
Time                    : 
 
Blood sample (at end of enoxaparin infusion) 
 
 
Taken on                      /               / 
   
Taken at                  :              
 
 
Enoxaparin infusion dose received:  
 
 
If AEs occurred during the infusion please complete AEs log 
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If stopped early:  
Reason for stopping enoxaparin 
 
If reason for stopping enoxaparin qualifies as AE – please complete AE log 
 
 
 
 
 
 
Date and time of disposal of enoxaparin infusion:              
                                                      /                 / 
 
                                                                : 
 
 
Person confirming disposal of remaining infusion  
 
 
Any adverse events:             Yes                                               No 
 
If yes adverse log completed        Yes    
 
 14 hours post PCI – End of study 
 
Date     /    /  
 
Time                    :              
 
PPCI details 
 
Access                  Occluded Vessel                     
 
Stent (type/dimensions)  
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Other vessels with > 50% stenosis (if applicable)  
  
Any bleeding events                 Yes                                                 No 
 
If yes: bleeding site?  
 
 
Any treatment needed?                Yes                                                No 
 
 
 
Stent thrombosis                        Yes                                               No 
 
 
Cause of stent thrombosis:  
 
 
Stent thrombosis and bleeding events to be recorded as AEs as well 
 
Any new adverse events (AEs/SAEs) 
 
  Yes     No 
 
If yes, AE/SAE log completed  
 
 
 
Concomitant medication checked and any changes recorded in medication 
section, specifying dose and regimen for each medication.  
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COMEDICATION SECTION  
 
Generic drug name, 
dose and regimen 
Date started or >1 
month 
Date 
stopped  
or 
conti
nuing 
 
 
 
- - / - - / - - - -    
  
- - / - - / - - - - 
 
 
 
 
- - / - - / - - - - 
  
- - / - - / - - - - 
 
 
 
 
- - / - - / - - - - 
  
- - / - - / - - - - 
 
 
 
 
- - / - - / - - - - 
  
- - / - - / - - - - 
 
 
 
 
- - / - - / - - - - 
  
- - / - - / - - - - 
 
 
 
 
- - / - - / - - - - 
  
- - / - - / - - - - 
 
 
 
 
- - / - - / - - - - 
  
- - / - - / - - - - 
 
 
 
 
- - / - - / - - - - 
  
- - / - - / - - - - 
 
 
 
 
- - / - - / - - - - 
  
- - / - - / - - - - 
 
 
 
 
- - / - - / - - - - 
  
- - / - - / - - - - 
 
 
 
 
- - / - - / - - - - 
  
- - / - - / - - - - 
 
 
 
 
- - / - - / - - - - 
  
- - / - - / - - - - 
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Name of person completing form   
 
 
 
 
Signature of person completing form  
 
 
Date of completion 
 
 
STUDY COMPLETION 
 
PRINCIPAL INVESTIGATOR’S DECLARATION  
 
By signing below, I declare that the information presented in this 
case report form accurately reflects clinical information obtained 
from the study participant and their medical records, including the 
results of tests and evaluations performed on the dates specified. 
 
Principal investigator 
 
 
Signature of principal investigator 
                                             
       
Date            __ __ / __ __ / __ __ __ __ 
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Supplementary	Laboratory	CRF	
	
Time	Point	1	Date	of	Sample	(DD:MMM:YYYY):		_	_._	_	_._	_	_	_		Time	of	Sample:		_	_:_	_			
VerifyNow	P2Y12		 	 	 	 	 	 Initials:	
____________		 PRU	 Base	 %	Inhibition	 Time	of	assay		 	 	 _	_:_	_		Comments:				
	
Fibrin	
	 Maximum	turbidity	(AU)	 	Lag	time		(secs)	 	Lysis	time	(secs)	 	
	
TEG	
In-tem	S	Reagent	Clotting	time	(CT)	(secs)	 	A10	(Amplitude	at	10	mins)	(mm)	 	CFT	(clot	formation	time)	(secs)	 	MCF	(maximum	clot	firmness	(mm)	 	
	
	
Anti	Xa	
	Level:																																																																																					.	(IU/ml)	
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Time	Point	2	Time	of	Sample:		_	_:_	_			
VerifyNow	P2Y12		 	 	 	 	 	 	
Initials:____________		 PRU	 Base	 %	Inhibition	 Time	of	assay		 	 	 _	_:_	_		Comments:		
	
	
Fibrin	
	 Maximum	turbidity	(AU)	 	Lag	time		(secs)	 	Lysis	time	(secs)	 	
	
TEG	
In-tem	S	reagent	Clotting	time	(CT)	(secs)	 	A10	(Amplitude	at	10	mins)	(mm)	 	CFT	(clot	formation	time)	(secs)	 	MCF	(maximum	clot	firmness	(mm)	 		
Anti	Xa	
	Level:																																																																																					.	(IU/ml)	
	
	
	
	
	
	
	
	
	
	
	
 145 
	
	
Time	Point	3	Time	of	Sample:		_	_:_	_			
VerifyNow	P2Y12		 	 	 	 	Initials:____________		 PRU	 Base	 %	Inhibition	 Time	of	assay		 	 	 _	_:_	_		Comments:		
Fibrin	
	 Maximum	turbidity	(AU)	 	Lag	time	(secs)	 	Lysis	time	(secs)	 	
	
TEG	
In-tem	S	reagent	Clotting	time	(CT)	(secs)	 	A10	(Amplitude	at	10	mins)	(mm)	 	CFT	(clot	formation	time)	(secs)	 	MCF	(maximum	clot	firmness	(mm)	 		
Anti	Xa	
	Level:																																																																																					.	(IU/ml)	
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Time	Point	4	Time	of	Sample:		_	_:_	_			
VerifyNow	P2Y12		 	 	 	 	 Initials:____________		 PRU	 Base	 %	Inhibition	 Time	of	assay		 	 	 _	_:_	_		Comments:		
 
Fibrin	
	 Maximum	turbidity	(AU)	 	Lag	time		(secs)	 	Lysis	time	(secs)	 	
	
TEG	
In-tem	S	reagent	Clotting	time	(CT)	(secs)	 	A10	(Amplitude	at	10	mins)	(mm)	 	CFT	(clot	formation	time)	(secs)	 	MCF	(maximum	clot	firmness	(mm)	 	
	
	
Anti	Xa	
	Level:																																																																																					.	(IU/ml)	
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